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 SUMMARY 
Human melanomas frequently harbor amplifications of EZH2. However, the contribution of this 
methyltransferase to melanoma formation has remained elusive. Taking advantage of murine melanoma 
models, we show that EZH2 drives tumorigenesis from benign BrafV600E or NrasQ61K-expressing 
melanocytes by silencing of genes relevant for the integrity of the primary cilium, a signaling organelle 
projecting from the surface of vertebrate cells. Consequently, gain of EZH2 promotes loss of primary cilia 
in benign melanocytic lesions. In contrast, blockade of EZH2 activity evokes ciliogenesis and cilia-
dependent growth inhibition in malignant melanoma. Finally, we demonstrate that loss of cilia enhances 
pro-tumorigenic WNT/β-catenin signaling and is itself sufficient to drive metastatic melanoma in benign 
cells. Thus, primary cilia deconstruction is a key process in EZH2-driven melanomagenesis. 
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 SIGNIFICANCE 
Aberrant activity of epigenetic modifiers, such as the histone methyltransferase EZH2, is thought to 
contribute to the formation of various cancer entities. Here we show that EZH2, in conjunction with 
oncogenic BRAF or NRAS, drives formation of metastatic melanoma. EZH2 exerts tumorigenicity through 
epigenetic silencing of genes relevant for the primary cilium, resulting in deconstruction of this signaling 
organelle and potentiation of WNT/β-catenin signaling. Importantly, primary cilium disassembly itself 
suffices to initiate WNT signaling-dependent melanoma. Loss of primary cilia and gain of β-catenin 
activity are hallmarks of many cancers. Thus, EZH2-mediated cilia deconstruction associated with WNT 
signal stimulation could, in principle, be relevant for tumor development in a variety of tissues. 
 
  
 INTRODUCTION 
In recent years, many studies have revealed dysregulation of Polycomb repressive complex 2 (PRC2) in 
cancer. PRC2 epigenetically suppresses gene transcription through tri-methylation of lysine 27 in histone 
3 (H3K27me3). Among others, the catalytic capacity of PRC2 can be potentiated by either overexpression 
or gain-of-function (GoF) mutations (e.g. Y646F, Y646N) of Enhancer of zeste homolog 2 (EZH2), the 
gene encoding the methyltransferase unit of PRC2 (Kim and Roberts, 2016). 
Recent attempts to decipher the significance of elevated PRC2 activity for tumorigenesis have revealed 
tissue-specific expression of wild-type (WT) Ezh2 to foster breast, prostate, and lung epithelial neoplasia 
in mice (Koppens et al., 2017; Li et al., 2009; Zhang et al., 2016). Expression of Ezh2Y646F or Ezh2Y646N in 
murine B-cells likewise drove hyperplastic transformation ultimately progressing into lymphoma 
(Béguelin et al., 2013; Berg et al., 2014; Souroullas et al., 2016). Moreover, in conjunction with BrafV600E, 
substitution of endogenous Ezh2 with Ezh2Y646F led to emergence of non-metastatic melanocytic tumors 
(Souroullas et al., 2016). In an autochthonous mouse model of malignant melanomagenesis, homozygous 
deletion of Ezh2 abolished cutaneous melanoma initiation and metastatic spread (Zingg et al., 2015). 
However, it remains unresolved whether a gain in EZH2 activity is sufficient to drive malignant metastatic 
melanoma. 
In solid cancers, together with cutaneous melanoma, PRC2 activity has been connected to regulation of 
cell proliferation and tumor growth through repression of tumor suppressors, such as CDKN1A and 
CDKN2A (Kim and Roberts, 2016). In the context of oncogenic NRASQ61K signaling and Cdkn2a gene 
knockout, mice spontaneously develop melanoma (Ackermann et al., 2005). Yet, in these animals, Ezh2 
ablation is sufficient to prevent tumor growth (Zingg et al., 2015). Hence, EZH2 might contribute to 
melanomagenesis by controlling genes beyond traditional tumor suppressors. 
  
 RESULTS 
Recurrent gains of EZH2 in human melanomas confer tumorigenesis 
Analysis of The Cancer Genome Atlas’ (TCGA) datasets on skin cutaneous melanoma (TCGA Network, 
2015) revealed the EZH2 locus to be amplified in 58.3% of melanoma samples. EZH2 copy number gains 
were associated with enhanced EZH2 transcription compared to samples with normal or loss of EZH2 
copy numbers (Figures 1A and S1A). This appeared to be independent of genetic subtypes, i.e. BRAF 
versus NRAS somatic GoF mutations, NF1 loss-of-function (LoF), and triple WT (Figures S1A and S1B). 
Furthermore, across several published gene expression datasets (Kabbarah et al., 2010; Scatolini et al., 
2010; Smith et al., 2005; Talantov et al., 2005), EZH2 levels were significantly increased in malignant 
melanomas in comparison to benign nevus samples (Figure 1B). 
These findings prompted us to investigate the functional relevance of EZH2 upregulation for 
melanomagenesis. We first expressed EZH2WT and EZH2Y646N in the melanoma cell line A375, which led 
to global gains in H3K27me3 (Figures S1C and S1D). EZH2WT and EZH2Y646N comparably triggered 
colony formation in A375 (Figure 1C). Importantly, the clonogenic potential depended on canonical 
EZH2 function, as inhibition of the catalytic activity of EZH2 using the chemical compound GSK503 
(Béguelin et al., 2013) largely abrogated A375 clonogenicity (Figures 1C and S1D). Next, we turned to a 
mouse model of melanoma, in which dermal hyperplasia formation reminiscent of human benign nevi is 
driven through a NrasQ61K transgene. In combination with a Cdkn2a knockout, few of these pre-malignant 
lesions progress into melanoma over time (Ackermann et al., 2005). We isolated RIH hyperplasia cells 
from NrasQ61K;Cdkn2a–/– mice using Cre-mediated R26R–lox-stop-lox-(LSL)–tdTomato cell labeling and 
fluorescence-activated cell sorting (FACS) (Figures 1D and S1E). When transplanted subcutaneously (SC) 
into immunocompromised Nude-Foxn1nu/nu mice, control RIH cells rarely gave rise to tumors. In contrast, 
despite low infection efficiency (Figure S1F), RIH cells expressing EZH2WT/Y646N formed malignant 
melanomas, which were fully tdTomato and ZsGreen1 positive (Figures 1E and S1G-S1I). Importantly, 
 through FACS analysis of lung tissue from tumor-bearing mice, we could identify tdTomato-ZsGreen1-
traced cells in this distant organ (Figure S1J). To verify whether EZH2WT/Y646N mediated melanoma 
formation in conjunction with endogenous murine EZH2, we used primary RIM-1 melanoma cells derived 
from a NrasQ61K;Cdkn2a–/– animal harboring floxed Ezh2 alleles (Zingg et al., 2015). ZsGreen1-
EZH2WT/Y646N-expressing RIM-1 cells were inoculated into immunosuppressed mice (Figures 1F and 
S1K). Efficient Ezh2 deletion in vivo via tamoxifen (TM) administration compromised RIM-1 tumor 
growth (Figures 1G and S1L-S1N). However, lack of endogenous Ezh2 was fully rescued through 
EZH2WT or EZH2Y646N expression, resulting in growing tumors predominantly comprised of ZsGreen1-
traced cells (Figures 1G and S1L-S1O). 
 
Ezh2Y646N induction enhances tumorigenesis in murine models of malignant melanoma 
To address whether EZH2 can initiate tumorigenesis in genetically engineered mouse models of 
melanoma, we used NrasQ61K;Cdkn2a–/– and BrafV600E;Pten–/– mice. In the latter, tumorigenesis is driven by 
synchronous conditional activation of BrafV600E and deletion of Pten (Dankort et al., 2009). We bred these 
animals with ColA1-LSL-Ezh2Y646N mice (Béguelin et al., 2013), allowing conditional Ezh2Y646N activation 
(Figure 2A). Topical 4-hydroxytamoxifen administration or intraperitoneal (IP) TM injection (Figure 2B) 
led to considerable EZH2Y646N expression in BrafV600E;Pten–/– and NrasQ61K;Cdkn2a–/– tumors. This 
resulted in increased H3K27me3 levels specifically in melanoma cells (Figures S2A-S2C). Proliferation 
rates were increased in BrafV600E;Pten–/–;Ezh2Y646N and NrasQ61K;Cdkn2a–/–;Ezh2Y646N tumor cells as 
compared to the respective controls (Figures 2C, 2D, and S2D). Consequently, tumors grew faster in 
BrafV600E;Pten–/–;Ezh2Y646N mice compared to BrafV600E;Pten–/– controls, resulting in a significantly 
shortened melanoma-specific survival (Figures 2E and S2E). Activation of Ezh2Y646N in NrasQ61K;Cdkn2a–
/– mice prior to tumor development (Figure 2B) resulted in both increased and quicker initiation of primary 
melanomas in comparison to controls (Figures 2F-2H). Inclusion of a R26R-LSL-tdTomato allele allowed 
fate-mapping of dermal hyperplasia cells (Figure 2A). Recombination efficiencies in control and 
 Ezh2Y646N GoF hyperplasia were about 50%. Accordingly, roughly half of all tumors emerging in 
NrasQ61K;Cdkn2a–/– animals were tdTomato-positive. However, Ezh2Y646N activation strongly increased the 
emergence of fully recombined melanomas at the expense of tdTomato-negative, non-recombined tumors, 
reflecting the tumor-promoting activity of EZH2Y646N (Figures 2I–2K). 
 
Ezh2Y646N drives metastatic melanoma from BrafV600E and NrasQ61K hyperplasia 
We next activated Ezh2Y646N in BrafV600E or NrasQ61K animals harboring proficient Pten and Cdkn2a 
(Figures 3A and 3B). BrafV600E and NrasQ61K mice form dermal hyperplasia, but malignant melanoma 
occurrence is sparse and observed only in mice older than 1 year (Ackermann et al., 2005; Dankort et al., 
2009). In absence of BrafV600E or NrasQ61K, expression of Ezh2Y646N affected neither the capacity of 
melanocytes to populate hair follicle bulbs nor hair pigmentation (Figures S3A-S3D). Ezh2Y646N alone was 
also insufficient to promote melanocytic hyperplasia (Figure 3C). However, in combination with NrasQ61K, 
Ezh2Y646N accelerated proliferation of dermal hyperplasia cells (Figure S3E), comparable to the increased 
proliferation of NrasQ61K;Cdkn2a–/–;Ezh2Y646N hyperplasia (Figure 2D). This led to enlarged dermal 
hyperplasia consisting of tdTomato-traced cells in NrasQ61K;Ezh2Y646N skin (Figures 3C and S3F). 
Strikingly, with a high incidence, Ezh2Y646N drove emergence of malignant melanomas from both benign 
NrasQ61K and BrafV600E hyperplasia (Figures 3D, 3E, and S3G). At the day of sacrifice, these mice 
displayed many more skin melanomas than NrasQ61K and BrafV600E controls (Figures 3F, 3G, and S3H). In 
contrast, animals bearing solely Ezh2Y646N never developed melanoma, independently of Pten or Cdkn2a 
deficiency (Figures 2E, 2H, 3D, and 3G). Of note, NrasQ61K;Ezh2Y646N and BrafV600E;Ezh2Y646N primary 
melanomas frequently metastasized to lymph nodes (Figures 3H and 3I). Cutaneous tumors and 
metastases were tdTomato-traced and, across the mouse cohorts, occurrence of metastases strongly 
correlated with prevalence of primary skin melanomas (Figures 3J-3L and S3I). Taken together, these data 
 show that, in conjunction with oncogenic BRAF or NRAS alleles, EZH2 functions as a bona fide driver of 
metastasizing cutaneous melanoma. 
 
EZH2 silences a gene network functionally connected to the primary cilium 
To decipher the molecular consequences of a gain of EZH2 in melanomagenesis, we FACS-isolated 
tdTomato-labeled dermal hyperplasia cells from NrasQ61K and NrasQ61K;Ezh2Y646N animals and performed 
RNA-sequencing (Figures S4A and S4B). Interestingly, among differentially expressed genes, we neither 
found tumor suppressors, such as Cdkn1a or Cdkn2a (Table S1), nor did gene ontology (GO) 
classification of biological processes reveal any terms related to cell cycle (Figure S4C). However, GO 
biological process and cellular component localization analyses revealed that a significant number of 
differentially expressed genes encoded proteins locating to the primary cilium (Figures 4A and S4C). The 
primary cilium is an organelle that projects from the surface of vertebrate cells and is a nexus for several 
signaling pathways (Goetz and Anderson, 2010). To substantiate a possible connection between PRC2 
epigenetics and primary cilium biology, we exploited published genome-wide gene expression profiles 
that were acquired from two human melanoma cell cultures following RNA interference (RNAi)-mediated 
EZH2 silencing (Zingg et al., 2015). In both cell lines, GO cellular component analyses revealed 
differentially expressed genes to be connected to the primary cilium (Figure S4D). Next, we established a 
group of genes changed in at least two of the three murine and human data sets (Figure 4B). Cellular 
component analysis on this subset of genes showed that most of the significantly enriched GO terms were 
related to primary cilium assembly or function (Figure 4C). According to the SYSCILIA gold standard list 
of known ciliary components (van Dam et al., 2013), the analyzed gene subset was comprised of about 
20% ciliary genes. These were predominantly downregulated upon gain of EZH2Y646N and upregulated 
after EZH2 silencing (Figure 4D). Finally, we analyzed global H3K27me3 landscapes of melanoma cells 
(Verfaillie et al., 2015). In comparison to a set of randomly selected genes, SYSCILIA genes harbored 
strong H3K27me3 enrichment flanking transcriptional start sites (TSS) (Figures 4E-4G, S4E, and S4F). 
 To pursue a possible connection between EZH2 activity and ciliary genes, we inhibited EZH2 with 
GSK503 in a panel of melanoma cell lines. This resulted in loss of H3K27me3 and upregulation of 
primary cilium genes (Figure S4G-S4J). Chromatin immunoprecipitation (ChIP) for H3K27me3 followed 
by qPCR revealed that the TSS of many ciliary genes had lost trimethylation of H3K27 upon GSK503 
(Figures S4K and S4L). In contrast, expression of both EZH2WT and EZH2Y646N in A375, a melanoma cell 
line with low H3K27me3 and high expression of ciliary genes (Figures S4H and S4M), resulted in 
downregulation of primary cilium genes, which was completely reversed when applying GSK503. 
Consequently, gain in EZH2 provoked reversible H3K27me3 enrichment in ciliary gene TSS (Figure 
S4N). 
To clarify whether increased EZH2 activity in vivo would also result in H3K27me3 deposition at cilia loci, 
we first used RIH tumors induced by EZH2WT/Y646N expression (Figure 1E). ChIP-qPCR revealed TSS of 
ciliary genes to be enriched in H3K27me3 as compared to negative control sequences (Figure S4O). Next, 
we FACS-isolated dermal hyperplasia cells from NrasQ61K or BrafV600E mice after Ezh2Y646N activation 
(Figure S4A). Importantly, ChIP-qPCR showed that, in these benign cells, Ezh2Y646N elicited strong 
H3K27me3 enrichment in cilia gene TSS. This appeared to be maintained in NrasQ61K;Ezh2Y646N tumors 
(Figure 4H). Accordingly, Ezh2Y646N induced ciliary gene silencing in NrasQ61K and BrafV600E hyperplasia, 
which was sustained throughout melanomagenesis (Figure 4I). Expression of Ezh2Y646N also led to 
downregulation of cilia genes in NrasQ61K;Cdkn2a–/– and BrafV600E;Pten–/– tumors. In contrast, conditional 
Ezh2 deletion in established NrasQ61K;Cdkn2a–/– melanomas resulted in re-expression of primary cilium 
genes (Figures S2A, S4P, and S4Q). Finally, within genome expression datasets on human melanocytic 
lesions, cilia genes were significantly downregulated in primary melanomas and metastases in comparison 
to benign nevi, a pattern that appeared to anti-correlate with EZH2 expression (Figure 4J). Thus, during 
human and murine melanoma formation, EZH2 suppresses genes functionally connected to the primary 
cilium. 
 
 Suppression of ciliary genes by EZH2 mediates primary cilium deconstruction 
We analyzed whether, across melanocytic lesions, the identified ciliary gene expression patterns coincided 
with the extent of ciliation. Indeed, benign nevi were ciliated, while malignant melanomas were mostly 
devoid of primary cilia (Figures 5A and S5A). In contrast, EZH2 levels were strongly increased in 
melanomas as compared to nevi, which negatively correlated with the presence of cilia (Figures 5A, 5B, 
and S5B). To verify whether EZH2-dependent repression of ciliary genes impaired primary cilium 
integrity, we reverted to melanoma cell cultures. Similar to melanocytes, which form primary cilia in 
starvation conditions (Le Coz et al., 2014), few of the melanoma cell lines tested were ciliated during 
starvation. The remaining lines only marginally displayed cilia (Figures 5C and S5C). Across the 
melanoma cell lines, percentages of ciliated cells correlated positively with the expression levels of 
primary cilia genes (Figure S4M). Moreover, relative H3K27me3 levels inversely correlated with cellular 
ciliation (Figure S5D), suggesting an EZH2 activity-dependent regulation of ciliogenesis. 
Indeed, EZH2 blockade with GSK503 induced primary cilium formation in most melanoma cell lines 
(Figure 5C), a process that significantly correlated with increased ciliary gene expression (Figure S4J). In 
A375, a melanoma cell line with considerable ciliation (Figure 5C), EZH2WT and EZH2Y646N expression 
comparably provoked cilia deconstruction specifically in transfected ZsGreen1-positive cells. However, 
EZH2 inhibition restored ciliogenesis despite EZH2 overexpression (Figure 5D). In vivo, Ezh2Y646N 
expression promoted loss of primary cilia in BrafV600E;Pten–/– melanomas (Figure 5E). NrasQ61K;Cdkn2a–/– 
tumors already displayed low percentages of ciliation, thus Ezh2Y646N gain did not further suppress cilia 
formation. In contrast, NrasQ61K;Cdkn2a–/– dermal hyperplasia cells were frequently ciliated, comparable 
to human benign nevi. However, Ezh2Y646N activation strongly reduced primary cilia numbers in 
NrasQ61K;Cdkn2a–/– dermal hyperplasia, while Ezh2 depletion resulted in ciliogenesis in established tumors 
(Figures 5F and S5E). Of note, Ezh2Y646N also led to loss of cilia in NrasQ61K dermal hyperplasia long 
before cutaneous melanoma formation (Figures 5G and S5E). Thus, EZH2-mediated deconstruction of 
primary cilia might represent an early event in malignant melanoma initiation. 
  
EZH2-mediated primary cilium disassembly augments WNT/β-catenin signaling 
A central function of the primary cilium lays in controlling key signaling pathways, especially sonic 
hedgehog (SHH) and wingless (WNT) signaling (Goetz and Anderson, 2010; Oh and Katsanis, 2013). To 
examine whether these pathways are controlled by ciliation in melanoma cells, we depleted EZH2-
regulated primary cilium genes in ciliated A375 melanoma cells and benign murine RIH cells. 
Manipulation of WDR19, FUZ, and IFT81 elicits cilia deconstruction (Ashe et al., 2012; Bhogaraju et al., 
2013; Gray et al., 2009). Accordingly, RNAi-mediated silencing of these genes resulted in loss of primary 
cilia in A375 cells (Figures S6A and S6B). Likewise, silencing of Wdr19 and Kif3a, a gene encoding a 
key ciliary component (Marszalek et al., 1999) that was, however, not regulated by EZH2, depleted cilia 
from RIH cells (Figures S6A and S6C). Treatment of A375 with WNT3A or SHH followed by luciferase 
reporter assays using constructs containing TCF/LEF or GLI1 promoter sequences showed that loss of 
primary cilia compromised SHH/GLI signaling, while it strongly enhanced canonical WNT/β-catenin 
signaling (Figure 6A). Upon cilia depletion, WNT3A also promoted TCF/LEF luciferase reporter activity 
in RIH cells (Figure S6D). In both A375 and RIH cells, elevated WNT signaling was associated with 
nuclear accumulation of total and especially non-phosphorylated, active β-catenin in deciliated cells 
(Figures 6B, S6E, and S6F). However, blockade of canonical WNT signaling with the chemical 
compounds JW55 or PRI-724 (Emami et al., 2004; Waaler et al., 2012) erased deciliation-induced β-
catenin activity, as revealed by β-catenin exclusion from the nucleus and reversal of TCF/LEF reporter 
responses (Figures 6B and S6F-S6H). 
WNT/β-catenin is an established oncogenic signaling pathway in human melanoma (Xue et al., 2016). 
Accordingly, nuclei of benign nevus cells were devoid of β-catenin, while malignant melanomas 
displayed accumulation of nuclear β-catenin (Figures 6C and S6I). Across melanocytic lesions, nuclear β-
catenin localization anti-correlated with presence of primary cilia, but significantly correlated with EZH2 
expression (Figures 6C, 6D, and S6J). To further dissect the association between WNT/β-catenin signaling 
 and EZH2-mediated loss of cilia, we expressed EZH2WT/Y646N in A375 and RIH cells. This provoked cilia 
deconstruction (Figure 5D) and consistently stimulated TCF/LEF reporter activity, expression of the WNT 
signaling reporter gene AXIN2 (Jho et al., 2002), and nuclear β-catenin accumulation. These responses 
were suppressed when either EZH2 was inhibited with GSK503 or WNT signaling was blocked using 
JW55 or PRI-724 (Figures 6E, 6F, and S6K-S6M). In vivo, induction of Ezh2Y646N resulted in Axin2 
upregulation in BrafV600E and NrasQ61K hyperplasia, which was maintained in NrasQ61K;Ezh2Y646N tumors 
(Figure 6G). Likewise, Ezh2Y646N activation boosted Axin2 expression in BrafV600E;Pten–/– and 
NrasQ61K;Cdkn2a–/– melanomas, whereas Ezh2 ablation reduced Axin2 expression in NrasQ61K;Cdkn2a–/– 
tumors (Figures 6H and S6N). Thus, enhanced EZH2 activity potentiates WNT/β-catenin signaling in 
benign melanocytic hyperplasia and melanoma. 
To functionally link EZH2-mediated deciliation to elevated WNT/β-catenin signaling, we relied on a 
melanoma cell culture (M130604) with low baseline ciliation but strong cilia induction upon EZH2 
blockade (Figure 5C). EZH2 inhibition considerably compromised WNT signal activation in response to 
WNT3A, as revealed by reduced TCF/LEF reporter activity, AXIN2 expression, and nuclear β-catenin 
accumulation. Strikingly, silencing of WDR19 or FUZ mediated deciliation and consequently resulted in 
reactivation of WNT signaling even in the presence of the EZH2 inhibitor GSK503 (Figures 6I and S6O-
S6S). However, the canonical WNT inhibitors JW55 and PRI-724 abrogated WNT/β-catenin signaling 
induction (Figure S6T). 
 
Primary cilium disassembly provokes melanoma cell growth 
To investigate the role of the primary cilium in melanomagenesis, we assessed whether cilia 
deconstruction mediated by ciliary gene depletion affects melanoma cell behavior. We found silencing of 
WDR19 and FUZ to enhance clonogenicity of human A375 and depletion of Wdr19 and Kif3a to 
substantially promote colony formation of murine RIH cells (Figures 7A-7C and S7A). Next, we silenced 
 cilia genes in human melanoma cell cultures, in which EZH2 inhibition strongly induced primary cilium 
assembly (Figure 5C). Ciliogenesis was reversed through RNAi against ciliary genes (Figures S6O-S6Q). 
Accordingly, depletion of ciliary genes partially restored cell proliferation despite EZH2 inactivation 
(Figure S7B), and loss of clonogenicity upon EZH2 blockade was overcome by WDR19 and FUZ 
silencing (Figures 7D and 7E). Hence, in vitro, deciliation counteracts growth suppression induced by 
EZH2 inhibition. 
To elucidate whether this phenotype emerged from enhanced WNT signaling, we suppressed β-catenin 
activity with JW55 or PRI-724. These inhibitors annihilated clonogenicity of A375 and RIH cells evoked 
by cilia deconstruction (Figures 7A-7C and S7A). Similarly, in EZH2-inhibited M130604 cells, 
clonogenicity re-acquired after deciliation was suppressed through WNT signaling inhibition (Figures 7D 
and 7E). JW55 and PRI-724 also prevented A375 and RIH colony formation induced by EZH2WT/Y646N 
expression (Figures S7C and S7D). Next, we tested 501Mel melanoma cells, which harbor an endogenous 
CTNNB1S37F mutation preventing β-catenin phosphorylation and degradation (Rubinfeld et al., 1997). 
Despite considerable de-repression of ciliary genes and formation of primary cilia upon EZH2 blockade 
(Figures 5C and S4J), 501Mel cells were resistant to EZH2 inhibition, as revealed by sustained β-catenin 
activity and colony formation (Figures S7E-S7G). Thus, we stimulated WNT signaling in M130604 cells, 
either by inducing β-catenin stabilization with the GSK-3 inhibitor Chiron or by expressing non-
degradable CTNNB1S33Y (Figures S7H and S7I). M130604 was sensitive to EZH2 blockade by displaying 
ciliogenesis-dependent loss of β-catenin signaling (Figures 6I and S6O-S6S). Notably, β-catenin 
stabilization with Chiron as well as CTNNB1S33Y expression significantly reversed the effect of EZH2 
inhibition on cell clonogenicity (Figure 7F). Taken together, in benign hyperplasia and malignant 
melanoma cells, EZH2-mediated primary cilium disassembly appears to promote clonogenicity via β-
catenin activation.  
 
Primary cilium deconstruction is a driver of malignant metastatic melanoma 
 Finally, we aimed to explore whether EZH2-dependent loss of primary cilia and gain in β-catenin is 
relevant for melanomagenesis in vivo. To this end, we suppressed primary cilia via Wdr19 silencing in 
primary murine RIM-3 cells (Figures 8A, S8A, and S8B). When inoculated SC into immunocompromised 
mice, RIM-3 cells maintained Wdr19 loss in vivo (Figure S8C). Daily IP administration of GSK503 
counteracted RIM-3 tumor growth. However, Wdr19 silencing strongly enhanced RIM-3 growth, which 
was sufficient to completely abrogate tumor growth control mediated by GSK503 (Figures 8B, 8C, and 
S8D). Interestingly, EZH2 inhibition reduced Axin2 expression in RIM-3 tumors. In contrast, despite 
EZH2 blockade, Wdr19 RNAi-dependent deciliation boosted WNT/β-catenin signaling in vivo, as 
revealed by Axin2 upregulation (Figure 8D). 
Next, we transplanted Wdr19 and Kif3a-depleted RIH cells SC into immunosuppressed mice (Figure 8E). 
Control RIH cells rarely gave rise to tumors. In contrast, Wdr19 as well as Kif3a-depleted RIH cells 
readily advanced into tdTomato-GFP double-positive melanomas upon transplantation (Figures 8F-8H 
and S8E-S8G). These tumors evidently metastasized to the lung, as we FACS-identified tdTomato-GFP-
traced cells in this organ (Figures 8I and S8H). We then expressed CTNNB1S33Y in RIH cells (Figures 8E 
and S8I). SC transplantation of these cells into immunocompromised mice similarly led to emergence of 
fully tdTomato-GFP traceable metastasizing melanomas (Figures 8J, 8K, and S8J-S8M). Thus, activation 
of β-catenin signaling in vivo was sufficient to initiate melanomagenesis. To verify whether melanoma 
initiation driven by EZH2 and primary cilium deconstruction was dependent on WNT signaling, we 
serially passaged tumors that had emerged from RIH cells through EZH2Y646N expression, Wdr19 
silencing, or Kif3a silencing (Figures 1E, 8G, and 8H). Daily oral administration of JW55 significantly 
reduced β-catenin in second-generation RIH tumors (Figures 8L and S8N). Strikingly, canonical WNT 
signaling inhibition strongly compromised growth of RIH-EZH2Y646N, RIH-shWdr19, and RIH-shKif3a 
melanomas (Figures 8M and S8O). Thus, EZH2 gain and primary cilium deconstruction are key drivers 
for the initiation of WNT/β-catenin signaling-addicted malignant melanoma in vivo.   
 DISCUSSION 
Recent publications have revealed that a large set of solid cancers exhibit loss of primary cilia (Cao and 
Zhong, 2016), in line with reduced ciliary gene expression (Shpak et al., 2014). However, the mechanisms 
by which cancer cells lose their cilia and the significance of cilia loss for tumorigenesis have remained 
elusive. Our study reveals how assembly and disassembly of the primary cilium are epigenetically 
regulated by PRC2. In particular, we identify the PRC2 component EZH2 to promote tumorigenesis by 
suppressing primary cilium genes, which results in deciliation. Ciliary deconstruction in turn initiates the 
formation of metastasizing melanoma by promoting WNT/β-catenin signaling. Thus, the primary cilium 
functions as a tumor suppressor organelle of malignant metastatic melanoma.  
About 67% of human primary melanomas and 56% of melanoma metastases display cytoplasmic or 
nuclear β-catenin accumulation (Xue et al., 2016). Of note, active β-catenin stimulates emergence of 
metastasizing melanoma in mice harboring BrafV600E or NrasQ61K hyperplasia (Damsky et al., 2011; 
Delmas et al., 2007; Gallagher et al., 2013). In several cancers, β-catenin activity is maintained mostly 
through genetic aberrations affecting either CTNNB1 itself or the β-catenin destruction complex member 
APC (Zhan et al., 2017). Although few melanomas harbor somatic CTNNB1 mutations (Xue et al., 2016), 
in most melanomas the sources of elevated β-catenin activity are unknown. In this study, we uncovered a 
mechanism of β-catenin induction that is independent of genetic alterations but relies on PRC2 activity 
and suppression of the primary cilium. Interestingly, enhanced PRC2 activity also propagates 
glioblastoma stem cells and initiates dysplasia formation from breast epithelium (Kim et al., 2013; Li et 
al., 2009). Moreover, in cells of the central nervous system and the mammary gland, depletion of cilia 
genes stimulates canonical WNT signaling (Oh and Katsanis, 2013), which is crucial for the formation of 
glioblastoma and breast cancer, respectively (Lee et al., 2016; Yu et al., 2016). Thus, the mechanism of 
primary cilium disruption discovered here could maintain oncogenic WNT/β-catenin signaling not only in 
a large portion of human melanomas but also in tumors of brain and breast. 
 Contrary to cutaneous melanoma, malignant peripheral nerve sheath tumors (MPNSTs) harbor LoF 
mutations abolishing PRC2 activity (De Raedt et al., 2014). Whether these tumors are ciliated is unknown. 
However, MPNSTs show a signature of elevated SHH signaling (Lévy et al., 2004), a pathway that 
strongly relies on the primary cilium (Goetz and Anderson, 2010). Likewise, emergence of basal cell 
carcinoma and medulloblastoma is dependent on both oncogenic SHH signaling and functional cilia (Han 
et al., 2009; Wong et al., 2009). Of note, Ezh2 deletion in a mouse model of medulloblastoma accelerates 
tumorigenesis (Vo et al., 2017). Upon disassembly of primary cilia via EZH2, we observed abrogated 
SHH signaling, whereas WNT signaling was enhanced. Interestingly, SHH-WNT antagonisms are 
required for neural tube morphogenesis as much as epidermal stem cell expansion (Ouspenskaia et al., 
2016; Ulloa and Briscoe, 2007), while the primary cilium counteractively controls these two signaling 
pathways (Goetz and Anderson, 2010; Oh and Katsanis, 2013). Taken together, acquiring either gain or 
loss of PRC2 might allow cancers to manipulate the primary cilium, thus ultimately skewing the SHH-
WNT interplay towards the preferential oncogenic signaling pathway. 
Recent immunotherapeutic advancements have resulted in remarkable clinical responses in some 
melanoma patients. However, the remaining patients frequently acquire resistance to immunotherapies 
(Sharma et al., 2017). Distinctive mechanisms in suppressing anti-tumor immunity involve tumor-intrinsic 
PRC2 activity as well as WNT/β-catenin signaling (Spranger et al., 2015; Zingg et al., 2017). Moreover, 
physical contact between cytotoxic T-cells and tumor cells depends on the formation of the cytolytic 
synapse. Assembly of that structure involves many of the proteins required for primary ciliogenesis (de la 
Roche et al., 2016). In principle, EZH2 could therefore foster immune escape by suppressing cytolytic 
synapses or primary cilium formation, the latter potentially increasing immunosuppressive WNT 
signaling. Several EZH2 inhibitors have entered clinical trials (Kim and Roberts, 2016). Thus, EZH2-
targeting might conceivably be considered as a strategy for treating melanoma, possibly in combination 
with immunotherapies.   
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 FIGURE LEGENDS 
Figure 1. EZH2 overexpression accelerates melanomagenesis 
(A) EZH2 mRNA expression in TCGA human skin cutaneous melanoma (SKCM) dataset segregated 
according to EZH2 copy numbers. Copy numbers, n < 2, 15 specimens; n = 2, 101 specimens; n > 2, 162 
specimens. RPKM, reads per kilobase million. 
(B) EZH2 mRNA expression in nevus (ne) and melanoma (me) datasets. GSE4587 (ne, n = 4; me, n = 9), 
GSE3189 (ne, n = 18; me, n = 45), GSE12391 (ne, n = 29; me, n = 23), GSE46517 (ne, n = 9; me, n = 
104). NE, normalized expression. 
(C) Clonogenicity of A375 transfected with empty vector, EZH2WT, or EZH2Y646N-expression plasmids 
and treated with GSK503. n = 3 independent experiments. 
(D) Strategy used to infect RIH cells with retro-empty vector, EZH2WT, or EZH2Y646N and transplant into 
Nude-Foxn1nu/nu mice. 
(E) Tumor growth curves of mice in (D). Empty vector, EZH2WT, each n = 8; EZH2Y646N, each n = 7 mice. 
(F) Strategy used to infect RIM-1 cells with retro-empty vector, EZH2WT, or EZH2Y646N, transplant into 
Nude mice, and treat with vehicle or tamoxifen (TM) to delete Ezh2. 
(G) Tumor growth curves of mice in (F). n = 5 mice per group. 
Data are represented as median ± interquartile range (box) and ± 100% range (whiskers) (A and B) or as 
mean ± standard error of the mean (SEM) (C and G). p values calculated with analysis of variance 
(ANOVA) and Fisher’s least significant difference (LSD) test (A, C, and G) or unpaired Student’s t-test 
(B). NS, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S1. 
  
 Figure 2. Ezh2Y646N promotes murine melanoma formation 
(A and B) Mouse genotypes (A) and strategies (B) used to analyze the effects of conditional Ezh2Y646N 
activation in the melanocytic lineage of adult BrafV600E;Pten–/– or NrasQ61K;Cdkn2a–/– mice. 4-OHT, 4-
hydroxytamoxifen. 
(C and D) Quantification of proliferative cells in tumors of BrafV600E;Pten–/– (C), n = 5 of 5; 
BrafV600E;Pten–/–;Ezh2Y646N (C), n = 6 of 6; NrasQ61K;Cdkn2a–/– (D), n = 12 of 9; and NrasQ61K;Cdkn2a–/–
;Ezh2Y646N (D) n = 12 of 10 mice. Hyperplasia in (D), each n = 5 of 5 mice. 
(E) Kaplan-Meier curves comparing melanoma-specific survival of Pten–/–;Ezh2Y646N, n = 3; 
BrafV600E;Pten–/–, n = 12; and BrafV600E;Pten–/–;Ezh2Y646N, n = 8 mice. 
(F) Melanoma count at time point of sacrifice. Cdkn2a–/–;Ezh2Y646N, n = 5; NrasQ61K;Cdkn2a–/–, n = 31; 
and NrasQ61K;Cdkn2a–/–;Ezh2Y646N, n = 21 mice. 
(G) NrasQ61K;Cdkn2a–/– and NrasQ61K;Cdkn2a–/–;Ezh2Y646N animal 3 months post TM. 
(H) Kaplan-Meier curves comparing melanoma-free survival. Mouse numbers as in (F). 
(I–K) Immunofluorescence staining for PAX3 and tdTomato (exemplified by NrasQ61K;Cdkn2a–/–
;Ezh2Y646N samples) (I) and quantification of recombination efficiencies (J) and recombination categories 
(K). D, dermis; E, epidermis. Arrowhead, PAX3+ tdTomato+ cell; empty arrowhead, PAX3+ tdTomato– 
cell. Scale bars, 50 μm. Hyperplasia, each n = 10 of 10 mice. Tumors, NrasQ61K;Cdkn2a–/–, n = 25 of 16 
(J), n = 36 of 21 (K); and NrasQ61K;Cdkn2a–/–;Ezh2Y646N, n = 35 (J), n = 49 (K) of 19 mice. 
Data are represented as mean ± SEM (C, D, and F) or as mean ± 100% range (J). p values calculated with 
unpaired Student’s t-test (C and F), ANOVA and Fisher’s LSD test (D and J), or log-rank (Mantel-Cox) 
test (E and H). See also Figure S2. 
  
 Figure 3. Ezh2Y646N is a driver of murine metastatic melanoma 
(A and B) Mouse genotypes (A) and strategies (B) used to analyze the effects of conditional Ezh2Y646N 
expression in the melanocytic lineage of adult BrafV600E and NrasQ61K mice. 
(C) Immunofluorescence staining for DCT to quantify hyperplasia size 5 months post TM. HF, hair 
follicle. Scale bars, 50 μm. Mouse numbers, WT, Ezh2Y646N, n = 2; NrasQ61K, n = 3; NrasQ61K;Ezh2Y646N, n 
= 4. 
(D and E) Kaplan-Meier curves comparing melanoma-free survival of Ezh2Y646N (D), n = 5; NrasQ61K (D), 
n = 30; NrasQ61K;Ezh2Y646N (D), n = 15; BrafV600E (E), n = 29; and BrafV600E;Ezh2Y646N (E), n = 24 mice. 
(F–I) Immunofluorescence staining for tdTomato on dorsal skin (F) and lymph nodes (LNs) (H) to 
quantify skin tumors (G) and metastatic burden (I). Scale bars, 1 mm. Mouse numbers as in (D and E). 
(J) Quantifications of recombination efficiencies in skin tumors and LN metastases. Each, n = 10 of 10 
mice. 
(K and L) Bar plots summarizing correlation between skin tumors and LN metastases within mouse 
cohorts from (D and E). 
Data are represented as median ± interquartile range (box) and ± 100% range (whiskers) (C) or as mean ± 
SEM (G, I, and J). p values calculated with unpaired Student’s t-test (C, G, and I), log-rank (Mantel-Cox) 
test (D and E), or Spearman’s rank correlation coefficient (rS) (K and L). See also Figure S3. 
 
  
 Figure 4. EZH2 suppresses transcription of primary cilium genes 
(A) PANTHER GO-slim cellular component analysis using Overrepresentation Test and Fisher’s Exact 
test with FDR multiple test correction on RNA-seq data from murine FACS-isolated NrasQ61K;Ezh2Y646N 
versus (vs.) NrasQ61K hyperplasia cells. 
(B) Genes commonly changed in NrasQ61K;Ezh2Y646N vs. NrasQ61K RNA-seq and in microarrays on 
M010817 and M050829 human melanoma cell cultures after EZH2 RNAi (GSE63165). 
(C) PANTHER GO cellular component complete analysis using Overrepresentation Test and Bonferroni 
correction on genes changed in n ≥ 2 of the datasets in (B). 
(D) Overlap of SYSCILIA genes and genes changed in n ≥ 2 of the datasets in (B), and heatmap depicting 
fold changes (FCs) of these genes. Colored squares, significant FCs over NrasQ61K cells (p < 0.01) or siCo 
transfected cells (p < 0.05). 
(E and F) Heatmaps (E) and enrichment plots (F) showing normalized read densities of H3K27me3 at the 
transcription start site (TSS) of SYSCILA and random genes (each n = 760) in MM034 (E and F) and 
MM118 (F) human melanoma cell cultures (GSE60666). Tracks are centered to the TSS and extend ± 5 
Kb. 
(G) Genome browser tracks showing H3K27me3 at WDR19 and TULP3 loci in human melanoma cell 
cultures (GSE60666). 
(H) Heatmaps showing H3K27me3 enrichments flanking TSS of ciliary genes in murine samples and p 
values from comparisons of individual groups. ChIP-qPCR normalized to input and H3K27me3 
enrichment in Rpl30 Intron 2 (I2) and intergenic region 1 (Interg1) of NrasQ61K and BrafV600E hyperplasia 
samples. Hyperplasia, each n = 5 of 5 mice; Tumors, n = 4 of 3 mice. 
(I) Heatmaps showing ciliary gene FCs in murine samples and p values from comparisons of individual 
groups. NrasQ61K, NrasQ61K;Ezh2Y646N hyperplasia, n = 6 of 6; NrasQ61K;Ezh2Y646N tumors, n = 4 of 3; and 
BrafV600E, BrafV600E;Ezh2Y646N hyperplasia, n = 4 of 4 mice. 
 (J) Heatmaps showing EZH2 and ciliary gene FCs in nevus and melanoma datasets and p values from 
comparisons of individual groups. N/A, not available. Datasets as in Figure 1B. 
p values calculated with ANOVA and Fisher’s LSD test (G, H, and I). See also Figure S4 and Table S1. 
 
  
 Figure 5. EZH2 expression leads to deconstruction of the primary cilium organelle 
(A and B) Immunofluorescence staining for MART1, acetylated tubulin (AcTub), and EZH2 on 
melanocytic lesions (A) to correlate ciliation and nuclear EZH2 intensity (B). Arrowhead, MART1+ 
AcTub (cilia)+ EZH2low cell; empty arrowhead, MART1+ AcTub– EZH2high cell. Nevi, congenital, 
intradermal, each n = 3; junctional, compound, each n = 4; Primary melanomas, n = 8; Metastases, skin, 
lymph node, each n = 5; distant, n = 7. 
(C) Immunofluorescence staining for ARL13B and PCNT to quantify ciliated melanoma cells during 
GSK503 treatment. 
(D) Endogenous ZsGreen1 (EZH2 expression vector) fluorescence and immunofluorescence staining for 
ARL13B and PCNT to quantify ciliated A375 cells transfected with empty vector, EZH2WT, or 
EZH2Y646N-expression plasmids and treated with GSK503. 
(E–G) Immunofluorescence stainings for ARL13B and SOX10, DCT, tdTomato, or β-Gal to quantify 
ciliated melanocytic cells. Arrowhead, ARL13B (cilia)+ and SOX10+, DCT+, tdTomato+, or β-Gal+ cell; 
empty arrowhead, ARL13B– and SOX10+, DCT+, or tdTomato+ cell. Tumors, BrafV600E;Pten–/–, n = 5 of 5; 
and BrafV600E;Pten–/–;Ezh2Y646N, n = 6 of 6 mice (E). Tumors and adjacent hyperplasia, NrasQ61K;Cdkn2a–/–
, n = 8 of 7; NrasQ61K;Cdkn2a–/–;Ezh2Y646N, n = 8 of 8; and NrasQ61K;Cdkn2a–/–;Ezh2–/–, n = 8 of 5 mice 
(F). NrasQ61K, NrasQ61K;Ezh2Y646N hyperplasia (5 months post TM), n = 6 of 6; and NrasQ61K;Ezh2Y646N 
tumors (endpoint), n = 8 of 6 mice (G). 
Scale bars, 25 μm. Data are represented as mean ± standard deviation (SD) (B) or mean ± SEM (C–G) of 
4 independent experiments (C and D). p values calculated with Spearman’s rS (B), unpaired Student’s t-
test (C and E), or ANOVA and Fisher’s LSD test (D, F, and G). See also Figure S5. 
  
 Figure 6. Loss of primary cilia induces WNT/β-catenin signaling 
(A) Luciferase reporter assays on A375 co-transfected with siCo, siWDR19, or siFUZ and empty vector, 
TCF/LEF, or GLI1 reporter plasmid after 3 hr stimulation with vehicle, WNT3A, or SHH. Relative 
luciferase units (RLU) calculated by normalizing firefly luciferase to Renilla luciferase luminescence. 
(B) Western blots for total and non-phosphorylated (nonP) β-catenin on cytoplasmic and nuclear fractions 
of A375 transfected with siCo, siWDR19, or siFUZ, treated with JW55, and stimulated with WNT3A. 
(C and D) Immunofluorescence staining for MART1, AcTub, and β-catenin on melanocytic lesions (C) to 
correlate ciliation and nuclear β-catenin localization (D). Arrowhead, MART1+ AcTub+ β-cateninlow cell; 
empty arrowhead, MART1+ AcTub– β-cateninhigh cell. Sample numbers as in Figure 5B. 
(E) Western blots for EZH2, H3K27me3, total, and nonP-β-catenin on cytoplasmic and nuclear fractions 
of A375 transfected with empty vector, EZH2WT, or EZH2Y646N-expression plasmids, treated with GSK503 
and JW55, and stimulated with WNT3A. 
(F) Luciferase reporter assays on RIH cells co-transfected with empty vector, EZH2WT, or EZH2Y646N-
expression and TCF/LEF reporter plasmids and treated with JW55 or PRI-724. All samples stimulated 
with WNT3A. 
(G) Axin2 mRNA expression in mouse hyperplasia and tumor samples. Numbers as in Figure 4I. 
(H) Axin2 mRNA expression in mouse tumor samples. Numbers as in Figure S4Q. 
(I) Immunofluorescence staining for nonP-β-catenin to quantify nuclear β-catenin in M130604 transfected 
with siCo, siWDR19, or siFUZ, treated with GSK503, and stimulated with WNT3A. 
Scale bars, 25 μm. Data are represented as mean ± SEM (A and F–H) of 3 independent experiments (A 
and F), as mean ± SD (D), or as median ± interquartile range (box) and ± 100% range (whiskers) of 2 
independent experiments (I). p values calculated with ANOVA and Fisher’s LSD test (A and F–I), 
Spearman’s rS (D), or unpaired Student’s t-test (G). See also Figure S6. 
  
 Figure 7. Primary cilium disassembly and WNT/β-catenin signaling promote melanoma growth 
(A and B) Colony formation assay (A) to quantify clonogenicity (B) of A375 transfected with siCo, 
siWDR19, or siFUZ and treated with JW55 or PRI-724. 
(C) Clonogenicity of RIH-1 infected with lenti-shCo, shWdr19, or shKif3a and treated with JW55 or PRI-
724. 
(D and E) Colony formation assay (D) to quantify clonogenicity (E) of M130604 transfected with siCo, 
siWDR19, or siFUZ and treated with GSK503, JW55, or PRI-724. 
(F) Colony formation assay to quantify clonogenicity of M130604 transfected with empty vector or 
CTNNB1S33Y-expression plasmid and treated with Chiron or GSK503. 
Data are represented as mean ± SEM of 4 independent experiments. p values calculated with ANOVA and 
Fisher’s LSD test. See also Figure S7. 
  
 Figure 8. Primary cilium deconstruction is sufficient to initiate metastatic melanoma 
(A) Strategy used to infect RIM-3 cells with lenti-shCo or shWdr19, transplanted into Nude mice, and 
treated with vehicle or GSK503. 
(B) Tumor growth curves of mice in (A). shCo + vehicle, n = 12; shCo + GSK503, n = 10; other groups, n 
= 5 mice. 
(C) Weight of tumors in (B) at endpoint. 
(D) Axin2 mRNA expression in tumors from (B). 
(E) Strategy used to infect RIH cells with lenti-shCo, shWdr19, shKif3a, empty vector, or CTNNB1S33Y 
and transplant into Nude mice. 
(F) Picture of shWdr19 mice in (E) at endpoint of shCo animals. 
(G and H) Tumor growth curves of shWdr19 (G) and shKif3a (H) mice in (E). shCo, each n = 14; 
shWdr19#2, each n = 8; other groups, each n = 5 mice. 
(I) FACS analyses to quantify GFP+ td-tomato+ RIH cells in lungs from mice in (G and H). 
(J) Tumor growth curves of CTNNB1S33Y mice in (E). Empty vector, each n = 5; CTNNB1S33Y, each n = 8 
mice. 
(K) FACS analyses to quantify GFP+ td-tomato+ RIH cells in lungs from mice in (J). 
(L) Western blots to quantify β-catenin intensities in second-generation tumors derived from RIH-1–
EZH2Y646N (Figure 1E), RIH-2–shWdr19#2 (G), or RIH-2–shWdr19#1 (H) tumors and treated with 
vehicle or JW55. n = 5 mice per group. 
(M) Tumor growth curves of mice in (L). 
Data are represented as mean ± SEM of 2 independent experiments (B–D and G–I) or one experiment (J–
M). p values calculated with ANOVA and Fisher’s LSD test (B–D and M), Kruskal-Wallis test with 
Dunn’s multiple comparisons test (I), Mann-Whitney U test (K), or unpaired Student’s t-test (L). See also 
Figure S8.   
 STAR METHODS 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be fulfilled by 
the Lead Contact, Lukas Sommer (lukas.sommer@anatomy.uzh.ch). 
 
  
 EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Mice 
3-month-old female Hsd:Athymic Nude-Foxn1nu/nu mice were purchased (Envigo). Mice carrying a Cre-
inducible Braf–lox-stop-lox-(LSL)–BrafV600E, R26R-LSL-LacZ, or R26R-LSL-tdTomato allele, a floxed 
Pten allele, or a Tyr::CreERT2 transgene were derived from The Jackson Laboratory. Mice carrying a 
floxed Ezh2 allele (Hirabayashi et al., 2009), a Cre-inducible ColA1-LSL-Ezh2Y646N allele (Béguelin et al., 
2013), or a Tyr::NrasQ61K transgene (Ackermann et al., 2005), and mice deficient for the Cdkn2a (INK4a) 
locus (Serrano et al., 1996) were kind gifts of Haruhiko Koseki (RIKEN Center for Integrative Medical 
Sciences, Japan), Kwok-Kin Wong (Dana-Farber Cancer Institute, USA), Friedrich Beermann (Swiss 
Federal Institute of Technology Lausanne, Switzerland), and Manuel Serrano (Centro Nacional de 
Investigaciones Oncologicas, Spain), respectively. These individual transgenic lines were crossed to 
achieve mouse genotypes indicated in (Figures 2A, 3A, S3A, and S4P). Genetic background of 
experimental animals was mixed. Mice were born with the expected ratio of Mendelian inheritance, and 
no changes in gender ratios were observed. Experimental mice were of both genders, and no apparent 
phenotypic differences between genders were observed. No statistical methods were used to predetermine 
sample size. For all experiments presented in this study, the sample size was large enough to measure the 
effect size. The experiments were not randomized and the investigators were not blinded to allocation 
during experiments and outcome assessment. The mouse colony was housed in a certified animal facility 
with a 12-hour light/dark cycle in a temperature-controlled room (22 ± 1 °C) with free access to water and 
food, in accordance with Swiss guidelines. All animal experiments were approved by the veterinary 
authorities of Canton of Zurich, Switzerland, and were performed in accordance with Swiss law and 
GlaxoSmithKline policy on the Care, Welfare, and Treatment of Animals. 
 
Human Material 
 Primary human materials were provided by the Tumor Biopsy and the Live Cell Biobanks of the 
University Research Priority Program (URPP) “Translational Cancer Research” (Mitchell P. Levesque, 
University Hospital Zurich). Biobanking of surplus, human material from consenting melanoma patients 
was performed according to the Declaration of Helsinki on Human Rights, and was approved by the 
Institutional Review Board (IRB) of Zurich (EK.647/800). All research on surplus human material was 
conducted under the IRB approval KEK-Zh.Nr 2014-0425. To ensure patient confidentiality no 
informations on age, gender, and ethnicity were provided to the investigators of this study.  
 
Cell Lines and Primary Cultures 
The human cell lines A375 (#CRL-1619, ATCC), HEK-293T (#CRL-3216, ATCC) SK-MEL-28 (#HTB-
72, ATCC), WM852 (#WM852-01-0001, Rockland), and WM983B (#WM983B-01-0001, Rockland) 
were purchased. Human melanoma cell lines 501Mel and 888Mel were described before (Rubinfeld et al., 
1997). Human melanoma short-term cell cultures M990514, M010817, M050829, M070302, M080423, 
M130604, and M140130 were established and genotyped by the URPP Live Cell Biobank (University of 
Zurich). HEK-293T cells were grown in DMEM (#41965, Thermo Fisher Scientific) supplemented with 
10% fetal bovine serum (FBS, #16140, Thermo Fisher Scientific). Melanoma cells were cultured in 
growth medium, which was RPMI 1640 (#42401, Thermo Fisher Scientific) supplemented with 10% FBS, 
4 mM L-Glutamine (#25030, Thermo Fisher Scientific), Penicillin-Streptomycin (#15070, Thermo Fisher 
Scientific), and Fungizone Antimycotic (#15290, Thermo Fisher Scientific). Murine primary cells derived 
from a NrasQ61K;Cdkn2a(INK4a)–/– melanoma (RIM-3), a NrasQ61K;Cdkn2a(INK4a)–/–
;Tyr::CreERT2;Ezh2lox/lox melanoma (RIM-1), or NrasQ61K;Cdkn2a(INK4a)–/– hyperplasia (RIH-1, RIH-2) 
were cultured on plates coated with fibronectin (#F1141, Sigma-Aldrich) using melanocyte medium, 
which was DMEM/F-12 (#21041, Thermo Fisher Scientific) supplemented with 10% FBS, Penicillin-
Streptomycin, and 200 nM 12-O-tetradecanoylphorbol 13-acetate (TPA, #P1585, Sigma-Aldrich). Prior to 
subjecting cells to functional in vitro assays, cells were grown for 48 hr in starvation medium, which was 
 growth medium supplemented with 1% FBS. All cells were cultured in CO2 cell culture incubators 
(Binder) at 37 °C with 5% CO2. 
  
 METHOD DETAILS  
Mouse genotyping 
Mouse biopsies were digested overnight at 55 °C using 150 μg/ml Proteinase K (#03115828001, Roche) 
in lysis buffer, which was 5 mM ethylenediaminetetraacetic acid (EDTA, #AM9261, Thermo Fisher 
Scientific), 200 mM sodium chloride (NaCl, #71380, Sigma-Aldrich), 0.2% sodium dodecylsulfate (SDS, 
#A2263, AppliChem), and 100 mM Tris hydrochloride (Tris-HCl, #A3452, AppliChem). Genomic DNA 
was precipitated with isopropanol (#1096341000, Merck Millipore) and resolved in water according to 
standard protocols followed by PCR using KAPA Taq ReadyMix with dye (#KK1024, Kapa Biosystems) 
and primers either recommended by The Jackson Laboratory or indicated in (Table S2). PCR products 
were segregated using agarose (#A8963, AppliChem) gel electrophoresis. 
 
In vivo gene activation and deletion 
To conditionally induce Ezh2Y646N, tdTomato, and BrafV600E expression, either Tyr::CreERT2;R26R-LSL-
tdTomato;ColA1-LSL-Ezh2Y646N;(Tyr::NrasQ61K;Cdkn2a–/–) or Tyr::CreERT2;R26R-LSL-tdTomato;Braf-
LSL-BrafV600E;ColA1-LSL-Ezh2Y646N mice were subjected to 5 consecutive daily intraperitoneal (IP) 
injections of 2 mg tamoxifen (TM, #T5648, Sigma-Aldrich) at an age of 4 weeks. To conditionally ablate 
Ezh2 alleles, Tyr::CreERT2;R26R-LSL-LacZ;Ezh2lox/lox;Tyr::NrasQ61K;Cdkn2a–/– animals were subjected to 
5 consecutive daily IP injections of 2 mg TM at an age of 5 to 7 months, when skin melanomas had 
become macroscopically measureable (Ø ≥ 2 mm), as described before (Zingg et al., 2015). In 
Tyr::CreERT2;Braf-LSL-BrafV600E;Ptenlox/lox;ColA1-LSL-Ezh2Y646N animals, Pten deletion and gene 
activation was achieved by topical administration of 80 μg 4-hydroxytamoxifen (4-OHT, #H7904, Sigma-
Aldrich) onto 2 cm2 of shaved back skin of 6-week-old mice. TM was diluted (10 mg/ml) in ethanol 
 (#20821.296, VWR Chemicals) and sunflower seed oil (#S5007, Sigma-Aldrich) (1:9), while 4-OHT was 
diluted (4 mg/ml) in dimethyl sulfoxide (DMSO, #D2650, Sigma-Aldrich) and ethanol (1:4). 
 
Trunk skin depilation 
To stimulate hair cycle progression in wild-type (WT) or Ezh2Y646N mice, animals were anaesthetized with 
isoflurane (#430024079, Piramal Healthcare) and dorsal skin was depilated using wax strips (Veet). First 
depilation was performed at 2 months of age and serially repeated every 1.5 months for three times. Mice 
were sacrificed 14 days after the last depilation, when stimulated hair cycle anagen was peaking. 
 
Quantification of skin melanomas and lymph node metastasis 
After 4-OHT application, melanoma growth on BrafV600E;Pten–/–;(Ezh2Y646N) animals was monitored every 
second day. Mice were sacrificed, when tumors showed ulceration. After TM administration, mice with a 
melanoma-prone genotype, i.e. NrasQ61K;(Ezh2Y646N), NrasQ61K;Cdkn2a–/–;(Ezh2Y646N), and 
BrafV600E;(Ezh2Y646N), were monitored weekly for appearance of skin melanomas. Developing trunk skin 
lesions were considered as melanomas when reaching a diameter of 2 mm (Ø ≥ 2 mm). Animals were 
sacrificed at an endpoint defined by adverse clinical symptoms including large skin tumors (Ø > 10 mm), 
ulcerating tumors, weight loss (Δm > 15%), or hunched back. At day of sacrifice, a final skin melanoma 
count was established. To quantify lymph nodes affected by metastatic melanoma, accessory axillary, 
proper axillary, sciatic, and subiliac lymph nodes (total of eight) were subjected to histological analysis 
identifying tdTomato+ melanoma cells. When conditionally deleting Ezh2 in NrasQ61K;Cdkn2a–/– mice 
bearing established skin melanoma, animals were monitored as described (Zingg et al., 2015) and 
sacrificed 4 weeks post TM administration. 
 
 Isolation of primary murine cells 
Short-term cell cultures isolated from NrasQ61K;Cdkn2a–/– tumors (RIM-1, RIM-3) were previously 
characterized (Zingg et al., 2015). To isolate dermal hyperplasia cells (RIH-1, RIH-2) from 
Tyr::CreERT2;R26R-LSL-tdTomato;Tyr::NrasQ61K;Cdkn2a–/– mice, melanocytic cells were fluorescently 
labeled in 3-month-old mice via Cre-mediated tdTomato activation using TM. To isolate hyperplasia cells 
from Tyr::CreERT2;R26R-LSL-tdTomato;Tyr::NrasQ61K;(ColA1-LSL-Ezh2Y646N) or Tyr::CreERT2;R26R-
LSL-tdTomato;Braf-LSL-BrafV600E;(ColA1-LSL-Ezh2Y646N) mice, tdTomato and transgenes were activated 
in melanocytic cells of 6-week-old animals. 4 weeks post recombination, dorsal trunk skin was dissected 
into small pieces and tissue was digested using 0.25 mg/ml Liberase DH Research Grade (#05401054001, 
Roche) in RPMI 1640 for 1 hr at 37 °C followed by a treatment with 0.2 mg/ml DNase I (#10104159001, 
Roche) for 15 min at 37 °C. Single cells were separated from remaining tissue using 40 μm Falcon Cell 
Strainers (#352340, Thermo Fisher Scientific) and resuspended in phosphate buffered saline (PBS, 
#10010, Thermo Fisher Scientific) containing 2 mM EDTA. Live tdTomato-traced cells were 
discriminated from dead cells using the LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (#L34975, 
Thermo Fisher Scientific) and isolated with a BD FACSAria III Cell Sorter (BD Biosciences) equipped 
with a 100 μm nozzle. Cells were collected into 1.5 ml Protein LoBind Tubes (#0030108116, Eppendorf) 
containing either 100% FBS for downstream live cell applications or Buffer RLT (#79216, Qiagen) with 
1% 2-mercaptoethanol (#M3148, Sigma-Aldrich) for total RNA isolation. 
 
Allografting of primary murine cells 
Immunocompromised Nude recipient mice were subcutaneously (SC) engrafted with 100,000 RIH or 
300,000 RIM cells suspended in RPMI 1640. When tumors became palpable, tumor size was measured 
every other day using a caliper. Mice were sacrificed when tumors reached a maximal volume of 1,500 
mm3. Tumor volume was calculated as follows: V = 2/3 × π × ((a + b)/4)3, a (mm) was the length and b 
 (mm) was the width of the tumor. All treatments of mice were initialized when tumors reached about a 
volume of 100 mm3. To block EZH2 activity in vivo, mice harboring RIM-3 tumors were subjected to 
daily IP injections of 150 mg/kg GSK503 EZH2 inhibitor (GlaxoSmithKline) until termination of the 
experiment. GSK503 was diluted (15 mg/ml) in 20% Captisol solution (#RC-0C7-100, Ligand 
Pharmaceuticals) and pH was adjusted to 5.3 using 1 M acetic acid (#320099, Sigma-Aldrich). In vivo 
efficacy of GSK503 has previously been evaluated (Béguelin et al., 2013; Zingg et al., 2015, 2017). To 
conditionally ablate Ezh2, mice harboring RIM-1 tumors were subjected to 5 consecutive daily IP 
injections of 2 mg TM as described previously (Zingg et al., 2015). To block canonical WNT/β-catenin 
signaling in vivo, mice harboring second-generation tumors originating from RIH cells were subjected to 
daily oral gavage administrations of 100 mg/kg JW55 tankyrase inhibitor (#406502, MedKoo 
Biosciences) until termination of the experiment. JW55 was diluted (20 mg/ml) in DMSO, ethanol, and 
tap water (3:3:4) and pH was adjusted to 5 using 1 M acetic acid. In vivo efficacy of JW55 was previously 
evaluated (Waaler et al., 2012). 
 
FACS analysis of tumors and lungs from allografted mice 
Upon sacrifice, tumors and lungs from Nude mice engrafted SC with RIH or RIM cells were dissociated 
using Liberase DH Research Grade and DNase I as described for NrasQ61K;Cdkn2a–/– mouse skin 
digestion. Single cells were separated from remaining tissue using a 40 μm cell strainer and resuspended 
in PBS with 2 mM EDTA. Live cells were distinguished from dead cells using the LIVE/DEAD Fixable 
Near-IR Dead Cell Stain Kit. tdTomato and ZsGreen1 or GFP double-positive cells were quantified with a 
BD FACSCanto II Flow Cytometer (BD Biosciences) and FlowJo software (Tree Star). 
 
Immunofluorescence on human and mouse tissue sections 
 3 μm sections of human paraffin-embedded nevus and melanoma biopsies were provided by the URPP 
Tumor Biopsy Biobank (University of Zurich). Mouse skin, tumor, and lymph node samples were fixed in 
4% Roti-Histofix (#P087.3, Carl Roth) overnight at 4 °C, embedded in paraffin, and sliced into 5 μm 
sections. Sections were deparaffinized as described before (Zingg et al., 2015). Sections were subjected to 
an antigen-unmasking step in citrate buffer (#S2369, Dako) using a microwave histoprocessor (Milestone) 
for 10 min at 110 °C and blocked with 1% BSA (#A4503, Sigma-Aldrich) in PBS and 0.05% Triton X-
100 (#T8787, Sigma-Aldrich) for 1 hr. Primary antibodies against acetylated tubulin (AcTub, #T7451, 
Sigma-Aldrich, 1:200), ARL13B (#17711-1-AP, Proteintech, 1:200), β-catenin (#sc-7199, Santa Cruz 
Biotechnology, 1:100), β-galactosidase (β-Gal, #ab9361, Abcam, 1:1,000), DCT (#ab74073, Abcam, 
1:200), DCT (#sc-10451, Santa Cruz Biotechnology, 1:200), EZH2 (#5246, Cell Signaling Technology, 
1:200), H3K27me3 (#9733, Cell Signaling Technology, 1:500), KI67 (#652402, BioLegend, 1:100), 
MART1 (#ab785, Abcam, 1:100), PAX3 (#38-1801, Thermo Fisher Scientific, 1:100), SOX10 (#sc-
17342, Santa Cruz Biotechnology, 1:100), and tdTomato (#LS-C340696, LifeSpan BioSciences, 1:500) 
were applied in Antibody Diluent (#S0809, Dako) overnight at 4 °C. Slides were washed with PBS 3 
times for 5 min. Primary antibodies were visualized using Alexa Fluor (AF)-488 anti-goat (#705-545-147, 
Jackson ImmunoResearch, 1:500), AF-488 anti-mouse IgG2b (#A-21141, Thermo Fisher Scientific, 
1:500), AF-488 anti-rabbit (#711-545-152, Jackson ImmunoResearch, 1:500), AF-488 anti-rat (#711-545-
153, Jackson ImmunoResearch, 1:500), Cy3 anti-goat (#705-165-147, Jackson ImmunoResearch, 1:500), 
Cy3 anti-rabbit (#711-165-152, Jackson ImmunoResearch, 1:500), Cy3 anti-rat (#711-165-153, Jackson 
ImmunoResearch, 1:500), AF-647 anti goat (#705-605-147, Jackson ImmunoResearch, 1:500), and AF-
633 anti-mouse IgG1 (#A-21126, Thermo Fisher Scientific, 1:500) secondary antibodies in Antibody 
Diluent for 1 hr at room temperature. For visualization of β-Gal and SOX10, biotinylated anti-chicken 
(#AP194B, Merck Millipore, 1:500) and anti-goat (#705-065-003, Jackson ImmunoResearch, 1:500) 
secondary antibodies were combined with further signal amplification using horseradish peroxidase-
streptavidin (#016-030-084, Jackson ImmunoResearch, 1:300) and the TSA Plus Cy3 Kit 
(#NEL744001KT, PerkinElmer, 1:50) according to manufacturers’ protocols. Subsequently, nuclear DNA 
 was stained with Hoechst 33342 (#14533, Sigma-Aldrich) and slides were mounted with Fluorescent 
Mounting Medium (#S3023, Dako). For skin derived from WT mice, samples were fixed in 4% Roti-
Histofix for 4 hr at 4 °C, immersed in 30% sucrose (#S0389, Sigma-Aldrich) overnight at 4 °C, and cryo-
preserved in Tissue-Tek O.C.T. Compound (#4583, Sakura). 12 μm cryo-sections were post-fixed in 2% 
formaldehyde (#F8775, Sigma-Aldrich) for 5 min. Immunofluorescent stainings were done as described 
for paraffin sections, except, to preserve endogenous tdTomato signal, antigen retrieval was avoided. 
Sections were recorded using either a DMI 6000B microscope (Leica) or an Axio Scan.Z1 slide scanner 
(Zeiss). 
 
Quantification of immunofluorescence on human and mouse tissue sections 
To quantify recombined hair follicles in murine WT skin, at least 100 hair follicles per sample were 
counted manually. For each mouse dermal hyperplasia sample, at least 15 dermal interfollicular areas 
were quantified. For each murine melanoma as well as human nevus or melanoma sample, at least 10 
fields were quantified. Therefore, DCT+ cells; tdTomato+ per PAX3+ or DCT+ cells; KI67+ per SOX10+ or 
PAX3+ cells; ARL13B (cilia)+ per SOX10+, DCT+, tdTomato+, or β-Gal+ cells; or AcTub (cilia)+ per 
MART1+ cells were identified and counted manually with ImageJ 1 software (Schneider et al., 2012). To 
measure nuclear H3K27me3 fluorescence intensity on murine melanoma sections, single fluorescence 
channels for H3K27me3, DCT or SOX10, and nuclear DNA were overlaid as separate layers in Photoshop 
CS5 software (Adobe). SOX10+ or DCT+ cells and DNA+ nuclei were selected using the “Magic Wand 
Tool”. SOX10 or DCT and nuclei-negative areas were then superimposed as “Darken” layers onto the 
H3K27me3 layer generating SOX10 or DCT and nuclei-specific H3K27me3 images. These images were 
quantified with CellProfiler software (Carpenter et al., 2006) using algorithms to “Identify Primary 
Objects” and to “Measure Object Intensity”. To quantify nuclear EZH2 and β-catenin fluorescence 
intensities on human nevi and melanoma samples, single fluorescence channels for EZH2 or β-catenin, 
 MART1, and nuclear DNA were processed with Photoshop CS5 and CellProfiler software as described for 
H3K27me3. 
 
Construction of CTNNB1S33Y lentivector 
Human CTNNB1S33Y cDNA was PCR-amplified from a pcDNA3.1-FLAG-CTNNB1S33Y plasmid (Valenta 
et al., 2011) by using High Fidelity PCR Master (#12140314001, Roche) and primers indicated in (Table 
S2) containing a BamHI or EcoRI restriction site. PCR product was segregated by agarose gel 
electrophoresis and purified with the QIAquick Gel Extraction Kit (#28704, Qiagen). PCR product and 
pMuLE-ENTR-CMV-L1-R5 vector (#62090, Addgene) were digested with FastDigest BamHI and EcoRI 
(#FD0054, #FD0274, Thermo Fisher Scientific), purified, and ligated using Anza T4 DNA Ligase Master 
Mix (#IVGN2108, Thermo Fisher Scientific). pMuLE-ENTR-CMV-CTNNB1S33Y-L1-R5, pMuLE-
ENTR-SV40-eGFP-L5-L2 (#62144, Addgene), and pLenti-X1-Puro-DEST (#17297, Addgene) vectors 
were subjected to L/R recombination using Gateway LR Clonase II Enzyme mix (#11791020, Thermo 
Fisher Scientific) as described previously (Albers et al., 2015). One Shot Stbl3 Chemically Competent E. 
coli (#C737303, Thermo Fisher Scientific) were transformed with pLenti-X1-Puro-CMV-CTNNB1S33Y-
SV40-eGFP vector, and plasmid was purified using QIAprep Spin Miniprep Kit (#27104, Qiagen) or 
NucleoBond Xtra Maxi Plus kit (#740416.10, Macherey-Nagel). 
 
Lentivirus and retrovirus production 
For lentivirus production, HEK-293T cells were co-transfected with 1 μg/ml of pLenti-eGFP, pLenti-
CTNNB1S33Y-eGFP, or plasmids expressing pGIPZ-non-silencing shRNA-TurboGFP (shCo, #RHS4346, 
Dharmacon), pGIPZ-shKif3a-TurboGFP (shKif3a#1/2, #RMM4431-20031-7419/8662, Dharmacon), or 
pGIPZ-shWdr19-TurboGFP (shWdr19#1/2, #VGM5520-20037-9129/7417, Dharmacon), in combination 
 with 0.25 μg/ml pMD2.G envelope-expressing plasmid (#12259, Addgene) and 0.55 μg/ml psPAX2 
packaging plasmid (#12260, Addgene). For retrovirus production, HEK-293T cells were transfected with 
1 μg/ml of pRetroX-IRES-ZsGreen1 (#632520, Clontech), pRetroX-EZH2WT-IRES-ZsGreen1, or 
pRetroX-EZH2Y646N-IRES-ZsGreen1, which have previously been validated (Béguelin et al., 2013; Zingg 
et al., 2015). Retroviral plasmids were combined with 1 μg/ml pCL-Ampho Retrovirus Packaging Vector 
(#NBP2-29541, Novus Biologicals). Efficient transfection was achieved with 2.5 M calcium chloride 
(CaCl2, #C1016, Sigma-Aldrich) in HEPES (#H4034, Sigma-Aldrich) buffer according to standard 
protocols. Supernatant containing viral particles was collected daily starting 24 hr post transfection. 
 
Stable gene silencing and expression 
Murine RIH or RIM cells were exposed to virus supernatant (50% supernatant, 50% melanocyte medium) 
containing either lentiviral particles encapsulating shCo-TurboGFP, shKif3a#1/2-TurboGFP, 
shWdr19#1/2-TurboGFP, eGFP, or CTNNB1S33Y-eGFP plasmids, or retroviral particles encapsulating 
ZsGreen1, EZH2WT-IRES-ZsGreen1, or EZH2Y646N-IRES-ZsGreen1 plasmids in combination with 10 
μg/ml Polybrene (#sc-134220, Santa Cruz Biotechnology) for 48 hr. Cells infected with retrovirus were 
directly subjected to experiments. Cells infected with lentivirus were selected with 1 μg/ml puromycin 
(#A11138-02, Thermo Fisher Scientific) for 1 week before subjection to experiments. 
 
Transient gene silencing and expression 
For transient gene silencing, human cells were transfected with Stealth siRNA Negative Control Med GC 
Duplex #2 (siCo, #12935112, Thermo Fisher Scientific) or siRNAs targeting FUZ (siFUZ#1/2/3, 
#HSS12946-0/2/1, Thermo Fisher Scientific), IFT81 (siIFT81#1/2/3, #HSS12077-6/7/5, Thermo Fisher 
Scientific), or WDR19 (siWDR19#1/2/3, #HSS1-26738/26737/84043, Thermo Fisher Scientific). 
 Therefore, 25 nM siRNA was applied in combination with jetPRIME Transfection Reagent (#114-15, 
Polyplus Transfection) according to manufacturer’s guidelines. For all functional assays, the most 
efficient siRNAs defined in (Figure S6A) were used. For transient gene expression, human cells were 
transfected with 1 μg/ml pLenti-eGFP, pLenti-CTNNB1S33Y-eGFP, pRetroX-IRES-ZsGreen1, pRetroX-
EZH2WT-IRES-ZsGreen1, or pRetroX-EZH2Y646N-IRES-ZsGreen1 plasmid in combination with jetPRIME 
Transfection Reagent according to manufacturer’s guidelines. 24 hr after transfections, growth medium 
was replaced by starvation medium and cells were subjected to further assays after 48 hr of starvation. 
 
In vitro inhibitor and growth factor applications 
To pharmacologically inhibit EZH2, cells were treated with either vehicle (DMSO) or 1 μM GSK503 for 
6 days in growth medium and for 48 hr in starvation medium before subjection to further assays. In vitro 
efficiency of GSK503 has been validated previously (Béguelin et al., 2013; Zingg et al., 2015). GSK503 
was only replenished upon medium exchange or passaging of cells. To prevent phosphorylation of β-
catenin via GSK-3 inhibition, cells were treated with either vehicle (DMSO) or 1 μM Chiron 
(CHIR99021, #1748-5, BioVision). To stimulate WNT/β-catenin or SHH/GLI signaling, cells were 
treated with vehicle (0.1% BSA in PBS), 100 ng/ml WNT3A (#5036-WN, R&D Systems), or 50 ng/ml 
SHH (#100-45, PeproTech) for 3 hr in starvation medium. To block canonical WNT/β-catenin signaling 
via tankyrase or CREB-binding protein inhibition, cells were threated with either vehicle (DMSO), 10 μM 
JW55 (#406502, MedKoo Biosciences), or 20 μM PRI-724 (#S8262, Selleckchem), respectively, for 48 hr 
in starvation medium before subjection to further assays. In vitro efficiencies of JW55 and PRI-724 have 
previously been validated (Emami et al., 2004; Waaler et al., 2012). JW55 and PRI-724 were replenished 
daily. 
 
Luciferase reporter assay 
 To report WNT/β-catenin or SHH/GLI signaling, cells were transfected with 300 ng/ml plasmid mix (40:1 
mixture of inducible firefly luciferase construct and constitutively expressing Renilla luciferase construct) 
from the TCF/LEF or the GLI Reporter Assay Kit (#336841, #CCS-018L and #CCS-6030L, Qiagen), 
respectively, using jetPRIME Transfection Reagent. Where applicable, cells were co-transfected with 300 
ng/ml luciferase reporter construct mix and either 25 nM siRNA or 1 μg/ml gene expression plasmid. 
Cells were starved and, where applicable, treated with WNT3A, SHH, GSK503, Chiron, JW55, or PRI-
724 as described above. Luciferase activity was measured with the Dual-Luciferase Reporter Assay 
System (#E1910, Promega) using a GloMax 96 Luminometer (#E5331, Promega). To standardize the 
transfection efficiency, luminescence levels of firefly luciferase were normalized to Renilla luciferase 
values. 
 
Colony formation and cell proliferation assays 
Cells transfected with siRNAs or plasmids were subjected to colony formation and cell proliferation 
assays 24 hr post transfection. To measure clonogenic potential, 500 cells per well were plated in 6-well 
plates in growth medium and, where applicable, subjected to GSK503, Chiron, JW55, or PRI-724 
treatment. When colonies reached a considerable size (n > 50 cells), cells were fixed with 4% Roti-
Histofix for 10 min and stained with Crystal violet solution (#HT90132, Sigma-Aldrich) for 30 min. 
Colonies (n > 50 cells) were counted manually using ImageJ 1 software. To measure cell proliferation, 
1,000 cells per well were plated in 96-well plates in growth medium and, where applicable, subjected to 
GSK503 treatment. Cell density was determined with the Cell Proliferation Kit I (MTT) (#11465007001, 
Roche) according to the supplier’s protocol starting 24 hr post seeding of the cells. Optical density was 
measured using a DTX 880 Multimode Detector (Beckman Coulter) at 595 nm. 
 
Immunofluorescence on cells 
 Cells were grown on glass cover slips, fixed with 4% Roti-Histofix for 8 min, and blocked with 1% BSA 
in PBS and 0.05% Triton X-100 for 1 hr. Cells were subjected to immunofluorescent labeling using 
primary antibodies against AcTub (#T7451, Sigma-Aldrich, 1:200), ARL13B (#17711-1-AP, Proteintech, 
1:500), non-phospho (nonP)-β-catenin (#8814, Cell Signaling Technology, 1:200), GFP (#GFP-1020, 
Aves Labs, 1:500), and PCNT (#ab28144, Abcam, 1:1,000) in blocking buffer overnight at 4 °C. Cells 
were washed with PBS 3 times for 5 min. Primary antibodies were visualized using AF-488 anti-mouse 
IgG2b (#A-21141, Thermo Fisher Scientific, 1:500), AF-488 anti-rabbit (#711-545-152, Jackson 
ImmunoResearch, 1:500), AF-546 anti-mouse (#A-11030, Thermo Fisher Scientific, 1:500), Cy3 anti-
rabbit (#711-165-152, Jackson ImmunoResearch, 1:500), AF-633 anti-mouse (#A-21052, Thermo Fisher 
Scientific, 1:500), AF-633 anti-mouse IgG1 (#A-21126, Thermo Fisher Scientific, 1:500), and AF-647 
anti-chicken (#103-605-155, Jackson ImmunoResearch, 1:500) secondary antibodies in blocking buffer 
for 1 hr at room temperature. Nuclei were stained with Hoechst 33342, and cells were recorded with a 
DMI 6000B microscope. 
For each replica, at least 10 fields were quantified. Therefore, AcTub+ or ARL13B+ cells or ARL13B+ per 
GFP+ or ZsGreen1+ cells were identified and counted manually with ImageJ 1 software. To measure 
nuclear β-catenin fluorescence intensity, single fluorescence channels for β-catenin and nuclear DNA 
were overlaid as separate layers in Photoshop CS5 software and DNA+ nuclei were selected using the 
“Magic Wand Tool”. Areas devoid of nuclei were superimposed as “Darken” layer onto the β-catenin 
layer.  These nuclear β-catenin images were quantified with CellProfiler software using algorithms to 
“Identify Primary Objects” and to “Measure Object Intensity”. 
 
Protein isolation 
For total protein isolation, cultured cells (500,000) and tumor biopsies (60 mg) were lysed in RIPA buffer 
(#89900, Thermo Fisher Scientific) containing Halt Protease and Phosphatase Inhibitor Cocktail (#78440, 
 Thermo Fisher Scientific). Homogenization of tumor biopsies was achieved by using a Polytron PT 2100 
tissue disperser (Kinematica). Cell lysis was completed using a SONOPULS HD 2070 Ultrasonic 
Homogenizer (Bandelin). To separate cytoplasmic and nuclear protein fractions, 10 Mio cells were 
subjected to sequential cytoplasmic and nuclear lysis using NE-PER Nuclear and Cytoplasmic Extraction 
Reagents (#78833, Thermo Fisher Scientific) containing Halt Protease and Phosphatase Inhibitor Cocktail 
according to manufacturer’s recommendations. Lysis of nuclear fraction was completed using a 
SONOPULS HD 2070 Ultrasonic Homogenizer. Protein concentrations were determined with the BCA 
Protein Assay Kit (#23227, Thermo Fisher Scientific) using a DTX 880 Multimode Detector at 562 nm. 
 
Western blotting 
Protein samples were denatured for 5 min at 95 °C with Laemmli Sample Buffer (#1610747, Bio-Rad) 
containing 10% 2-mercaptoethanol. 20 μg of protein per lane was loaded onto 4-20% Mini-PROTEAN 
TGX Gels (#4561094, #4561096, Bio Rad) and SDS-PAGE was carried out in Tris/Glycine/SDS Buffer 
(#1610732, Bio-Rad) for 1 hr with 120 V. Protein was transferred to nitrocellulose membranes using 
Nitrocellulose/Filter Paper Sandwiches (#1620215, Bio-Rad) with Tris/Glycine Buffer (#1610734, Bio-
Rad) containing 20% methanol (#106009, Merck-Millipore) for 1 hr at 4 °C with 2 mA. Nitrocellulose 
membranes were blocked with Odyssey blocking buffer (#927–40000, LI-COR Biosciences) for 1 hr. 
Primary antibodies against β-actin (#A5316, Sigma-Aldrich, 1:10,000), total β-catenin (#sc-7199, Santa 
Cruz Biotechnology, 1:1,000), nonP-β-catenin (#8814, Cell Signaling Technology, 1:1,000), EZH2 
(#5246, Cell Signaling Technology, 1:1,000), histone 3 (#3638, Cell Signaling Technology, 1:2,000), 
H3K27me2 (#9728, Cell Signaling Technology, 1:1,000), or H3K27me3 (#9733, Cell Signaling 
Technology, 1:2,000) were applied in Odyssey blocking buffer overnight at 4 °C. Membranes were 
washed with PBS containing 0.1% TWEEN 20 (#P1379, Sigma-Aldrich) (PBS-T) 3 times for 10 min. 
Primary antibodies were visualized using IRDye-800CW anti-mouse (#926-32212, LI-COR Biosciences, 
1:10,000) and IRDye-680LT anti-rabbit (#926-68023, LI-COR Biosciences, 1:10,000) secondary 
 antibodies in Odyssey blocking buffer for 45 min at room temperature. To remove antibodies, 
nitrocellulose membranes were treated with NewBlot Nitro Stripping Buffer (#928-40030, LI-COR 
Biosciences) for 15 min. Prior to antibody re-exposure, membranes were washed with PBS-T 3 times for 
10 min. Blots were scanned with an Odyssey imaging system (LI-COR Biosciences) and quantified with 
ImageJ 1 software. Quantified band intensities were normalized using either β-actin or histone 3 as 
housekeeping protein. Histone 3 was used as marker to survey accurate protein fractionation. 
 
RNA isolation and reverse transcriptase reaction 
Cultured cells (500,000) were lysed in Buffer RLT containing 1% 2-mercaptoethanol, while frozen tumor 
biopsies (40 mg) were homogenized in such buffer using a Polytron PT 2100 tissue disperser. Subsequent 
total RNA extraction and DNase treatment of samples was performed using the RNeasy Mini Kit (#74104, 
Qiagen) and the RNase-Free DNase Set (#79254, Qiagen) according to manufacturer’s guidelines. 
Purified RNA was quantified using a NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific) 
and subjected to reverse transcriptase (RT) reaction using the Maxima First Strand cDNA Synthesis Kit 
(K1641, Thermo Fisher Scientific) followed by a RNase H (EN0202, Thermo Fisher Scientific) digestion 
step according to manufacturer’s recommendations. At least 20,000 tdTomato-traced hyperplasia cells 
from NrasQ61K;(Ezh2Y646N) or BrafV600E;(Ezh2Y646N) mice were FACS-isolated into 1.5 ml Protein LoBind 
Tubes containing Buffer RLT with 1% 2-mercaptoethanol. Subsequent total RNA extraction and DNase 
treatment of samples was performed using the RNeasy Micro Kit (#74004, Qiagen) according to 
manufacturer’s guidelines. Total RNA was subjected to Quantiscript RT reaction and REPLI-g SensiPhi 
DNA amplification using the REPLI-g WTA Single Cell Kit (#150063, Qiagen) according to 
manufacturer’s recommendations. 
 
Genomic DNA isolation from tumor biopsies 
 Frozen tumor biopsies (25 mg) were lysed and genomic DNA was purified with the QIAamp Fast DNA 
Tissue Kit (#51404, Qiagen) following manufacturer’s guidelines. 
 
Chromatin isolation and ChIP of human cells 
Chromatin isolation and chromatin immunoprecipitation (ChIP) of human cultured cells was performed 
with the SimpleChIP Enzymatic Chromatin IP Kit (#9003, Cell Signaling Technology) according to 
manufacturer’s guidelines. 10 Mio cultured cells were crosslinked on culture plates with 1% formaldehyde 
for 10 min and subjected to chromatin isolation. Isolated nuclei were digested with 5 μl micrococcal 
nuclease for 30 min at 37 °C and nuclei were lysed using a SONOPULS HD 2070 Ultrasonic 
Homogenizer. Chromatin digestion efficiency was verified by agarose gel electrophoresis and chromatin 
concentration was determined with a NanoDrop ND-1000 Spectrophotometer. The ChIP was performed 
with 20 μg chromatin and a primary antibody against H3K27me3 (#9733, Cell Signaling Technology, 
1:100) or an IgG control antibody (#2729, Cell Signaling Technology, 1:100). 
 
Chromatin isolation and ChIP of mouse tissue and cells 
Frozen mouse tumors (100 mg) were chopped into small pieces, resuspended in PBS, and crosslinked with 
1% formaldehyde for 10 min. Reaction was stopped with 100 mM glycine (#G8898, Sigma-Aldrich). 
Tissue suspensions were washed twice with PBS and homogenized with a Dounce tissue grinder set 
(Sigma-Aldrich) until single cell suspensions were obtained. The cell pellet was resuspended in buffer A, 
which was 100 mM Tris-HCl with 10 mM DL-Dithiothreitol (#43815, Sigma-Aldrich), and incubated for 
15 min on ice followed by shaking for 15 min at 30 °C. Cells were centrifuged at 3,000 x g and 
resuspended in buffer B, which was 10 mM EDTA, 10 mM EGTA (#E3889, Sigma-Aldrich), 10 mM 
HEPES, and 0.25% Triton X-100, and incubated for 10 min on ice. Next, the cell pellet was resuspended 
 in buffer C, which was 10 mM EDTA, 0.5 mM EGTA, 10 mM HEPES, and 200 mM NaCl, and incubated 
for 5 min on ice. Chromatin was treated with 90 units Nuclease S7 (#10107921001, Roche) in 500 μl 
MNase buffer, which was 300 mM sucrose, 50 mM Tris-HCl, 30 mM potassium chloride (#P9333, 
Sigma-Aldrich), 7.5 mM NaCl, 4 mM CaCl2, 0.125% Nonidet P 40 Substitute (NP-40, #74385, Sigma-
Aldrich), and 0.25% sodium deoxycholate (#30970, Sigma-Aldrich), supplemented with Halt Protease and 
Phosphatase Inhibitor Cocktail, for 1 hr at 37 °C. Nuclease S7 digestion was stopped with 5 mM EDTA 
and 0.01% SDS. Samples were sonicated for 5 cycles using a Bioruptor sonication device (Diagenode). 
Chromatin digestion quality and concentration was verified by agarose gel electrophoresis. 
At least 50,000 tdTomato-traced hyperplasia cells from NrasQ61K;(Ezh2Y646N) or BrafV600E;(Ezh2Y646N) mice 
were FACS-isolated into 1.5 ml Protein LoBind Tubes containing 100% FBS. Cells were pelleted at 3,000 
x g, resuspended in 10% FBS in PBS, and crosslinked with 1% formaldehyde for 10 min. Reaction was 
stopped with 100 mM glycine for 10 min. Cells were washed once with 10% FBS in PBS, and chromatin 
preparation was done as described previously (Gilfillan et al., 2012). Briefly, chromatin was treated with 
0.1 units Nuclease S7 in 100 μl MNase digestion buffer, which was 50 mM Tris-HCl, 1 mM CaCl2, and 
0.2% Triton X-100, supplemented with Halt Protease and Phosphatase Inhibitor Cocktail, for 30 min at 37 
°C. Nuclease S7 digestion was stopped with 11 mM Tris-HCl, 5.5 mM EDTA, and 0.1% SDS. Samples 
were sonicated for 5 cycles using a Bioruptor sonication device. 
The ChIP was performed with 20 μg chromatin diluted in ChIP buffer, which was 16.7 mM Tris-HCl, 167 
mM NaCl, 1.2 mM EDTA, 0.01 % SDS, and 1.1 % Triton X-100. Chromatin was pre-cleared with Protein 
A-Sepharose CL-4B (#17-0780-01, GE Healthcare) on rotation for 2 hr at 4 °C. Supernatant was 
transferred to a clean 1.5 ml tube and incubated with primary antibody against H3K27me3 (#39155, 
Active Motif, 1:100) on rotation overnight at 4 °C. Immunoprecipitation was done with Dynabeads 
Protein A (#10002D, Thermo Fisher Scientific) with rotation for 4 hr at 4 °C. Beads were immobilized on 
a magnetic rack (#Z5342, Promega) and washed for 5 min twice with wash buffer 1, which was 16.7 mM 
Tris-HCl, 0.167 M NaCl, 0.1% SDS, and 1% Triton X-100; once with wash buffer 2, which was 16.7 mM 
 Tris-HCl, 0.5 M NaCl, 0.1 % SDS, and 1% Triton X-100; and twice with wash buffer 3, which was 0.25 
M lithium chloride (#L4408, Sigma-Aldrich), 0.5% sodium deoxycholate, 10 mM Tris-HCl, 1 mM EDTA, 
and 0.5% NP-40. Chromatin was eluted from the beads with 300 μl of 1% SDS and 100 mM sodium 
bicarbonate (#S6297, Sigma-Aldrich) for 30 min at 37 °C. Beads were immobilized on a magnetic rack 
and supernatant was transferred to a clean 1.5 ml tube. For reverse-crosslinking, 50 mM Tris-HCl, 250 
mM NaCl, and 12.5 mM EDTA were added and chromatin was incubated with 21.2 mg/ml Proteinase K 
for 1 hr at 50 °C, then overnight at 65 °C. DNA was purified with 300 μl Phenol-Chloroform-Isoamyl 
Alcohol (#P3803, Sigma-Aldrich). Water phase was collected in a clean 1.5 mL tube containing 30 μl of 3 
M sodium acetate (#W302406, Sigma-Aldrich) and 1 μl of glycogen (#G0885, Sigma-Aldrich). DNA was 
precipitated with ethanol and resolved in water. 
 
Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) was performed with LightCycler 480 Multiwell Plates 
(#04729692001, Roche) and a LightCycler 480 System (Roche). For cDNA and genomic DNA, qPCR 
was done with LightCycler 480 SYBR Green I Master (#4707516001, Roche). Primers were designed 
with Primer-BLAST (Ye et al., 2012) and are indicated in (Table S2). Where indicated, a Custom RT2 
PCR Array (#330171, Qiagen) spotted with primers for human primary cilium genes and GAPDH was 
used. Relative quantified cDNA was normalized using either mouse Usf1, human USF1, or, for primary 
cilium PCR plates, GAPDH as housekeeping transcript. Relative quantified genomic DNA was 
normalized using murine Rpl30 Intron 2 (#7015P, Cell Signaling Technology) as housekeeping sequence. 
For DNA derived from ChIPs, qPCR was done with KAPA SYBR Fast qPCR Kit Master Mix (#KR0389, 
KAPA Biosystems). ChIP Primers were specified to amplify genomic DNA from a region flanking the 
transcriptional start site (TSS) –500 bp to +100 bp devoid of local CpG islands defined by The UCSC 
Genome Browser (Kent et al., 2002) and CpG island prediction (Li and Dahiya, 2002). Primers were 
designed with Primer-BLAST and are indicated in (Table S2). Relative enrichment was normalized to 
 chromatin inputs and to mouse intergenic region 1 (Interg1), mouse Rpl30 Intron 2, or human RPL30 
Exon 3 (#7014P, Cell Signaling Technology) genomic DNA negative control sequences. 
 
RNA-sequencing 
Total RNA was purified as described above for NrasQ61K;(Ezh2Y646N) hyperplasia cells. Total RNA 
quantity and quality was determined using the Qubit 4 Quantitation Starter Kit (#Q33227, Thermo Fisher 
Scientific) and a 4200 TapeStation System (#G2991AA, Agilent). Illumina sequencing libraries were 
prepared with the SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian (#635005, Clontech) 
including ribosomal cDNA cleavage following manufacturer’s recommendations. Quantity and quality of 
the enriched libraries were validated using the Qubit 4 Quantitation Starter Kit and a 4200 TapeStation 
System aiming for an average fragment size of approximately 360 bp. The libraries were normalized to a 
10 nM concentration in 10 mM Tris-HCl and 0.1% TWEEN 20. Clusters were generated with 10 pM of 
pooled normalized libraries using the HiSeq 3000/4000 SR Cluster Kit (#GD-410-1001, Illumina) and a 
cBot 2 System (#SY-312-2001, Illumina). Sequencing was performed using the HiSeq 3000/4000 SBS Kit 
(#FC-410-1001, Illumina) on a HiSeq 4000 Sequencing System (#SY-401-4001, Illumina) at 125 bp 
single-end reads. 
 
RNA-sequencing analyses 
Raw reads were quality-checked using FastQC (Babraham Bioinformatics) and sequencing adapters were 
removed with Trimmomatic (Bolger et al., 2014). At least 20-base-long reads with an overall average 
Phred quality score greater than 10 were aligned to the reference genome of M. musculus 
(GRCm38/mm10) using STAR 2.5.1b (Dobin et al., 2013) with default settings for single-end reads. 
Distribution of the reads across genomic isoform expression and differentially expressed genes were 
 quantified with Bioconductor 3.0 software using the R packages GenomicRanges (Lawrence et al., 2013) 
and edgeR (Robinson et al., 2010), respectively. Genes were considered differentially expressed when 
displaying at least 10 counts in at least half of the samples of one group, FDR < 0.005, p < 0.01, and Log2 
FC > 0.7 / < –0.7. PANTHER gene ontology (GO)-slim biological processes and cellular component 
analyses were performed using Overrepresentation Test and Fisher’s Exact test with FDR multiple test 
correction (Mi et al., 2013). 
 
ChIP-sequencing analyses 
The published genomic H3K27me3 ChIP-seq profiles on malignant melanoma cell cultures GSE60666 
(Verfaillie et al., 2015) were analyzed for H3K27me3 peak enrichment in the TSS of SYSCILIA genes 
(van Dam et al., 2013) versus random genes. Heatmaps and enrichment profiles were plotted ± 5 Kb from 
TSS using deepTools2 with plotHeatmap and plotProfile functions (Ramírez et al., 2016). Genome 
browser track snapshots were generated with Integrative Genomic Viewer (Robinson et al., 2011). 
 
Microarray and TCGA analyses 
The microarray gene expression analysis of GSE63165 has been described previously (Zingg et al., 2015). 
PANTHER GO cellular component complete analysis was performed using Overrepresentation Test and 
Bonferroni correction (Mi et al., 2013). The published gene expression datasets on benign nevus and 
malignant melanoma samples GSE4587 (Smith et al., 2005), GSE3189 (Talantov et al., 2005), GSE12391 
(Scatolini et al., 2010), and GSE46517 (Kabbarah et al., 2010) were analyzed for expression of EZH2 and 
selected cilia genes by normalizing individual values to the mean of nevus samples within each dataset. 
The Cancer Genome Atlas (TCGA)’s normalized RSEM gene expression, GISTIC2 copy number, and 
oncotated mutation files for skin cutaneous melanoma (SKCM) (TCGA Network, 2015) were downloaded 
 from the Broad Institute’s GDAC Firehose (https://gdac.broadinstitute.org). All TCGA analyses were 
performed in R. 
  
 QUANTIFICATION AND STATISTICAL ANALYSIS 
Statistical analyses are described in each figure legend and were performed using GraphPad Prism 7 or R. 
For comparison of two groups, p values were calculated with a two-sided unpaired Student’s t-test. For 
comparison of more than two groups, p values were calculated using analysis of variance (ANOVA) with 
Geisser-Greenhouse correction and Fisher’s least significant difference (LSD) test. For comparing FACS 
analyses, p values were calculated with a nonparametric two-sided Mann-Whitney U test or a 
nonparametric Kruskal-Wallis test with Geisser-Greenhouse correction and Dunn’s multiple comparisons 
test. For comparison of Kaplan-Meier curves, p values were calculated with the log-rank (Mantel-Cox) 
test. Significance of correlations was calculated by using Spearman’s rank correlation coefficient (rS). For 
all statistical analyses, the expected variance was similar between the groups that were compared, and 
significance was accepted at the 95% confidence level (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 
0.0001). 
 
DATA AND SOFTWARE AVAILABILITY 
The accession number for the data reported in this paper is GSE112677 and can be accessed via the 
following link https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112677 
 
 KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse IgG2b Monoclonal Anti-Acetylated 
Tubulin Antibody 
Sigma-Aldrich Cat# T7451; RRID: AB_609894 
Mouse IgG2a Monoclonal Anti-β-Actin 
Antibody 
Sigma-Aldrich Cat# A5316; RRID: AB_476743 
Rabbit Polyclonal Anti-ARL13B Antibody Proteintech Cat# 17711-1-AP; RRID: AB_2060867 
Rabbit Polyclonal Anti-β-Catenin Antibody Santa Cruz Biotechnology Cat# sc-7199; RRID: AB_634603 
Rabbit Monoclonal Anti-Non-Phospho β-Catenin 
Antibody 
Cell Signaling Technology Cat# 8814; RRID: AB_11127203 
Chicken Polyclonal Anti-β-Galactosidase 
Antibody 
Abcam Cat# ab9361; RRID: AB_307210 
Rabbit Polyclonal Anti-DCT Antibody Abcam Cat# ab74073; RRID: AB_1524517 
Goat Polyclonal Anti-DCT Antibody Santa Cruz Biotechnology Cat# sc-10451; RRID: AB_793582 
Rabbit Monoclonal Anti-EZH2 Antibody Cell Signaling Technology Cat# 5246; RRID: AB_10694683 
Chicken Polyclonal Anti-GFP Antibody Aves Labs Cat# GFP-1020; RRID: AB_10000240 
Rabbit Monoclonal Anti-H3K27me2 Antibody Cell Signaling Technology Cat# 9728; RRID: AB_1281337 
Rabbit Monoclonal Anti-H3K27me3 Antibody Cell Signaling Technology Cat# 9733; RRID: AB_2616029 
Rabbit Polyclonal Anti-H3K27me3 Antibody Active Motif Cat# 39155; RRID: AB_2561020 
Mouse IgG1 Monoclonal Anti-Histone 3 
Antibody 
Cell Signaling Technology Cat# 3638; RRID: AB_1642229 
Rat IgG2a Monoclonal Anti-KI67 Antibody BioLegend Cat# 652402; RRID: AB_11204254 
Mouse IgG1 Monoclonal Anti-MART1 Antibody Abcam Cat# ab785; RRID: AB_306135 
Rabbit Polyclonal Anti-PAX3 Antibody Thermo Fisher Scientific Cat# 38-1801; RRID: AB_2533359 
Mouse IgG1 Monoclonal Anti-PCNT Antibody Abcam Cat# ab28144; RRID: AB_2160664 
Goat Polyclonal Anti-SOX10 Antibody Santa Cruz Biotechnology Cat# sc-17342; RRID: AB_2195374 
Goat Polyclonal Anti-tdTomato Antibody LifeSpan BioSciences Cat# LS-C340696 
Rabbit IgG Control Antibody Cell Signaling Technology Cat# 2729; RRID: AB_1031062 
Donkey Anti-Goat IgG (H+L) Secondary 
Antibody, Alexa Fluor 488 
Jackson ImmunoResearch Cat# 705-545-147; RRID: AB_2336933 
Goat Anti-Mouse IgG2b Secondary Antibody, 
Alexa Fluor 488 
Thermo Fisher Scientific Cat# A-21141; RRID: AB_2535778 
Donkey Anti-Rabbit IgG (H+L) Secondary 
Antibody, Alexa Fluor 488 
Jackson ImmunoResearch Cat# 711-545-152; RRID: AB_2313584 
Donkey Anti-Rat IgG (H+L) Secondary 
Antibody, Alexa Fluor 488 
Jackson ImmunoResearch Cat# 712-545-153; RRID: AB_2340684 
Goat anti-Mouse IgG (H+L) Secondary 
Antibody, Alexa Fluor 546 
Thermo Fisher Scientific Cat# A-11030; RRID: AB_2534089 
Donkey Anti-Goat IgG (H+L) Secondary 
Antibody, Cy3 
Jackson ImmunoResearch Cat# 705-165-147; RRID: AB_2307351 
Donkey Anti-Rabbit IgG (H+L) Secondary 
Antibody, Cy3 
Jackson ImmunoResearch Cat# 711-165-152; RRID: AB_2307443 
Donkey Anti-Rat IgG (H+L) Secondary 
Antibody, Cy3 
Jackson ImmunoResearch Cat# 712-165-153; RRID: AB_2340667 
Goat Anti-Mouse IgG (H+L) Secondary 
Antibody, Alexa Fluor 633 
Thermo Fisher Scientific Cat# A-21052; RRID: AB_2535719 
Goat Anti-Mouse IgG1 Secondary Antibody, 
Alexa Fluor 633 
Thermo Fisher Scientific Cat# A-21126; RRID: AB_2535768 
Goat Anti-Chicken IgY (H+L) Secondary 
Antibody, Alexa Fluor 647 
Jackson ImmunoResearch Cat# 103-605-155; RRID: AB_2337392 
Donkey Anti-Goat IgG (H+L) Secondary 
Antibody, Alexa Fluor 647 
Jackson ImmunoResearch Cat# 705-605-147; RRID: AB_2340437 
Donkey Anti-Chicken IgY (H+L) Secondary 
Antibody, Biotin 
Merck Millipore Cat# AP194B; RRID: AB_92675 
Key Resource Table
 Donkey Anti-Goat IgG (H+L) Secondary 
Antibody, Biotin 
Jackson ImmunoResearch Cat# 705-065-003; RRID: AB_2340396 
Donkey Anti-Mouse IgG (H+L) Secondary 
Antibody, IRDye-800CW 
LI-COR Biosciences Cat# 926-32212; RRID: AB_621847 
Donkey Anti-Rabbit IgG (H+L) Secondary 
Antibody, IRDye-680LT 
LI-COR Biosciences Cat# 926-68023; RRID: AB_10706167 
Bacterial and Virus Strains 
One Shot Stbl3 Chemically Competent E. coli Thermo Fisher Scientific Cat# C737303 
Lentiviral-shCo-TurboGFP This paper N/A 
Lentiviral-shWdr19#1-TurboGFP This paper N/A 
Lentiviral-shWdr19#2-TurboGFP This paper N/A 
Lentiviral-shKif3a#1-TurboGFP This paper N/A 
Lentiviral-shKif3a#2-TurboGFP This paper N/A 
Lentiviral-eGFP This paper N/A 
Lentiviral-CTNNB1S33Y-eGFP This paper N/A 
Retroviral-ZsGreen1 This paper N/A 
Retroviral-EZH2WT-IRES-ZsGreen1 This paper N/A 
Retroviral-EZH2Y646N-IRES-ZsGreen1 This paper N/A 
Biological Samples 
Human: Benign nevus paraffin sections URPP Tumor Biopsy Biobank, UZH N/A 
Human: Malignant melanoma paraffin sections URPP Tumor Biopsy Biobank, UZH N/A 
Human: Melanoma short-term cell cultures URPP Live Tumor Cell Biobank, UZH N/A 
Mouse: NrasQ61K;Cdkn2a–/– , NrasQ61K;Cdkn2a–/–
;Ezh2Y646N , NrasQ61K;Cdkn2a–/–;Ezh2–/– tumors 
This paper N/A 
Mouse: BrafV600E;Pten–/– , BrafV600E;Pten–/–
;Ezh2Y646N tumors 
This paper N/A 
Mouse: Primary NrasQ61K;Cdkn2a–/– tdTomato+ 
dermal hyperplasia cells (RIH-1) 
This paper N/A 
Mouse: Primary NrasQ61K;Cdkn2a–/– tdTomato+ 
dermal hyperplasia cells (RIH-2) 
This paper N/A 
Mouse: Primary NrasQ61K;Cdkn2a–/–
;Tyr::CreERT2;Ezh2lox/lox melanoma cells (RIM-1) 
(Zingg et al., 2015) N/A 
Mouse: Primary NrasQ61K;Cdkn2a–/– melanoma 
cells (RIM-3) 
(Zingg et al., 2015) N/A 
Chemicals, Peptides, and Recombinant Proteins 
Acetic acid, 99.7% Sigma-Aldrich Cat# 320099; CAS# 64-19-7 
Agarose AppliChem Cat# A8963; CAS# 9012-36-6 
Antibody Diluent Dako Cat# S0809 
Bovine Serum Albumin (BSA) Sigma-Aldrich Cat# A4503; CAS# 9048-46-8 
Calcium chloride Sigma-Aldrich Cat# C1016; CAS# 10043-52-4 
Captisol Ligand Pharmaceuticals Cat# RC-0C7-100 
Chiron (CHIR99021), GSK-3 inhibitor BioVision Cat# 1748-5; CAS# 252917-06-9 
Crystal violet solution Sigma-Aldrich Cat# HT90132; CAS# 548-62-9 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Cat# D2650; CAS# 67-68-5 
DL-Dithiothreitol Sigma-Aldrich Cat# 43815; CAS# 3483-12-3 
DNase I Roche Cat# 10104159001; CAS# 9003-98-9 
Dynabeads Protein A Thermo Fisher Scientific Cat# 10002D 
Ethanol absolut VWR Chemicals Cat# 20821.296; CAS# 64-17-5 
Ethylenediaminetetraacetic acid (EDTA), 0.5 M Thermo Fisher Scientific Cat# AM9261; CAS# 60-00-4 
EGTA Sigma-Aldrich Cat# E3889; CAS# 67-42-5 
Falcon Cell Strainers, 40 μm Thermo Fisher Scientific Cat# 352340 
Fetal Bovine Serum (FBS) Thermo Fisher Scientific Cat# 16140 
Fibronectin Sigma-Aldrich Cat# F1141 
Fluorescent Mounting Medium Dako Cat# S3023 
Formaldehyde Solution, 37% Sigma-Aldrich Cat# F8775; CAS# 50-00-0 
Fungizone Antimycotic Thermo Fisher Scientific Cat# 15290 
Glycine Sigma-Aldrich Cat# G8898; CAS# 56-40-6 
Glycogen Sigma-Aldrich Cat# G0885; CAS# 9005-79-2 
 L-Glutamine Thermo Fisher Scientific Cat# 25030 
GSK503, EZH2 inhibitor GlaxoSmithKline CAS# 1346572-63-1 
Halt Protease and Phosphatase Inhibitor Cocktail Thermo Fisher Scientific Cat# 78440 
HEPES Sigma-Aldrich Cat# H4034; CAS# 7365-45-9 
Hoechst 33342 Sigma-Aldrich Cat# 14533; CAS# 23491-52-3 
Horseradish Peroxidase-Streptavidin Jackson ImmunoResearch Cat# 016-030-084 
4-Hydroxytamoxifen (4-OHT) Sigma-Aldrich Cat# H7904; CAS# 68047-06-3 
Isoflurane Piramal Healthcare Cat# 430024079 
Isopropanol Merck Millipore Cat# 1096341000; CAS# 67-63-0 
JW55, Tankyrase inhibitor MedKoo Biosciences Cat# 406502; CAS# 664993-53-7 
Laemmli Sample Buffer, 4X Bio-Rad Cat# 1610747 
Liberase, DH Research Grade Roche Cat# 05401054001 
LightCycler 480 Multiwell Plate 96, white Roche Cat# 04729692001 
Lithium chloride  Sigma-Aldrich Cat# L4408; CAS# 7447-41-8 
Medium, DMEM Thermo Fisher Scientific Cat# 41965 
Medium, DMEM/F-12 Thermo Fisher Scientific Cat# 21041 
Medium, RPMI 1640 Thermo Fisher Scientific Cat# 42401 
2-Mercaptoethanol Sigma-Aldrich Cat# M3148; CAS# 60-24-2 
Methanol Merck Millipore Cat# 106009; CAS# 67-56-1 
4-20% Mini-PROTEAN TGX Gels Bio-Rad Cat# 4561094, 4561096  
 
NewBlot Nitro Stripping Buffer, 5X LI-COR Biosciences Cat# 928-40030 
Nitrocellulose/Filter Paper Sandwiches Bio-Rad Cat# 1620215 
Nonidet P 40 Substitute Sigma-Aldrich Cat# 74385; CAS# 9016-45-9 
Nuclease S7 Roche Cat# 10107921001; CAS# 9013-53-0 
Odyssey Blocking Buffer LI-COR Biosciences Cat# 927-40000 
Penicillin-Streptomycin Thermo Fisher Scientific Cat# 15070 
Phenol-Chloroform-Isoamyl Alcohol Sigma-Aldrich Cat# P3803 
Phosphate Buffered Saline (PBS), pH 7.4 Thermo Fisher Scientific Cat# 10010 
Polybrene Santa Cruz Biotechnology Cat# sc-134220 
Potassium chloride Sigma-Aldrich Cat# P9333; CAS# 7447-40-7 
PRI-724, Canonical WNT signaling inhibitor Selleckchem Cat# S8262; CAS# 847591-62-2 
Protein A-Sepharose CL-4B GE Healthcare Cat# 17-0780-01 
Protein LoBind Tubes Eppendorf Cat# 0030108116 
Proteinase K, recombinant PCR grade Roche Cat# 03115828001 
Puromycin Thermo Fisher Scientific Cat# A11138-02 
RIPA Buffer Thermo Fisher Scientific Cat# 89900 
RLT Buffer Qiagen Cat# 79216 
RNase H Thermo Fisher Scientific Cat# EN0202 
Roti-Histofix, 4% Carl Roth Cat# P087.3 
SHH, Recombinant human protein PeproTech Cat# 100-45 
Sodium acetate, anhydrous Sigma-Aldrich Cat# W302406; CAS# 127-09-3 
Sodium bicarbonate Sigma-Aldrich Cat# S6297; CAS# 144-55-8 
Sodium chloride Sigma-Aldrich Cat# 71380; CAS# 7647-14-5 
Sodium deoxycholate Sigma-Aldrich Cat# 30970; CAS# 302-95-4 
Sodium dodecylsulfate AppliChem Cat# A2263; CAS# 151-21-3 
Sucrose Sigma-Aldrich Cat# S0389; CAS# 57-50-1 
Sunflower seed oil Sigma-Aldrich Cat# S5007; CAS# 8001-21-6 
Tamoxifen (TM) Sigma-Aldrich Cat# T5648; CAS# 10540-29-1 
Target Retrieval Solution, Citrate pH 6 Dako Cat# S2369 
Tetradecanoylphorbol 13-acetate (TPA) Sigma-Aldrich Cat# P1585; CAS# 16561-29-8 
Tissue-Tek O.C.T. Compound Sakura Cat# 4583 
Tris Hydrochloride AppliChem Cat# A3452; CAS# 1185-53-1 
Tris/Glycine Buffer, 10X Bio-Rad Cat# 1610734 
Tris/Glycine/SDS Buffer, 10X Bio-Rad Cat# 1610732 
Triton X-100 Sigma-Aldrich Cat# T8787; CAS# 9002-93-1 
Trypsin-EDTA, 0.25% Thermo Fisher Scientific Cat# 25200 
TWEEN 20 Sigma-Aldrich Cat# P1379; CAS# 9005-64-5 
 Wax strips Veet N/A 
WNT3A, Recombinant human protein R&D Systems Cat# 5036-WN 
Critical Commercial Assays 
Anza T4 DNA Ligase Master Mix Thermo Fisher Scientific Cat# IVGN2108 
BCA Protein Assay Kit Thermo Fisher Scientific Cat# 23227 
Cell Proliferation Kit I (MTT) Roche Cat# 11465007001 
Cignal Reporter Assay Kit, GLI1 Qiagen Cat# 336841, CCS-6030L 
Cignal Reporter Assay Kit, TCF/LEF Qiagen Cat# 336841, CCS-018L 
Dual-Luciferase Reporter Assay System Promega Cat# E1910 
FastDigest BamHI Thermo Fisher Scientific Cat# FD0054 
FastDigest EcoRI Thermo Fisher Scientific Cat# FD0274 
High Fidelity PCR Master Roche Cat# 12140314001 
HiSeq 3000/4000 SBS Kit  Illumina Cat# FC-410-1001 
HiSeq 3000/4000 SR Cluster Kit Illumina Cat# GD-410-1001 
Gateway LR Clonase II Enzyme mix Thermo Fisher Scientific Cat# 11791020 
jetPRIME Transfection Reagent Polyplus Transfection Cat# 114-15 
KAPA SYBR Fast qPCR Kit Master Mix Kapa Biosystems Cat# KR0389 
KAPA Taq ReadyMix With Dye Kapa Biosystems Cat# KK1024 
LightCycler 480 SYBR Green I Master Roche Cat# 4707516001 
LIVE/DEAD Fixable Near-IR Dead Cell Stain 
Kit 
Thermo Fisher Scientific Cat# L34975 
Maxima First Strand cDNA Synthesis Kit Thermo Fisher Scientific Cat# K1641 
NE-PER Nuclear and Cytoplasmic Extraction 
Reagents 
Thermo Fisher Scientific Cat# 78833 
NucleoBond Xtra Maxi Plus kit Macherey-Nagel Cat# 740416.10 
QIAamp Fast DNA Tissue Kit Qiagen Cat# 51404 
QIAprep Spin Miniprep Kit Qiagen Cat# 27104 
QIAquick Gel Extraction Kit Qiagen Cat# 28704 
Qubit 4 Quantitation Starter Kit Thermo Fisher Scientific Cat# Q33227 
REPLI-g WTA Single Cell Kit Qiagen Cat# 150063 
RNase-Free DNase Set Qiagen Cat# 79254 
RNeasy Micro Kit Qiagen Cat# 74004 
RNeasy Mini Kit Qiagen Cat# 74104 
SimpleChIP Enzymatic Chromatin IP Kit Cell Signaling Technology Cat# 9003 
SMARTer Stranded Total RNA-Seq Kit - Pico 
Input Mammalian 
Clontech Cat# 635005 
TSA Plus Cy3 Kit PerkinElmer Cat# NEL744001KT 
Deposited Data 
Human: Microarray data (Talantov et al., 2005) GEO: GSE3189 
Human: Microarray data (Smith et al., 2005) GEO: GSE4587 
Human: Microarray data (Scatolini et al., 2010) GEO: GSE12391 
Human: Microarray data (Kabbarah et al., 2010) GEO: GSE46517 
Human: Microarray data (Zingg et al., 2015) GEO: GSE63165 
Human: TCGA-SKCM, normalized RSEM gene 
expression, GISTIC2 copy number, and 
oncotated mutation files 
(TCGA Network, 2015), Broad Institute, 
GDAC Firehose 
https://gdac.broadinstitute.org 
Human: ChIP-sequencing data (Verfaillie et al., 2015) GEO: GSE60666 
Mouse: RNA-sequencing data This paper GEO: GSE112677  
Experimental Models: Cell Lines 
Human: A375 cell line ATCC Cat# CRL-1619; RRID: CVCL_0132 
Human: HEK-293T cell line ATCC Cat# CRL-3216; RRID: CVCL_0063 
Human: SK-MEL-28 cell line ATCC Cat# HTB-72; RRID: CVCL_0526 
Human: WM852 cell line Rockland Cat# WM852-01-0001; RRID:CVCL_6804 
Human: WM983B cell line Rockland Cat# WM983B-01-0001; RRID:CVCL_6809 
Human: 501Mel cell line (Rubinfeld et al., 1997) RRID: CVCL_4633 
Human: 888Mel cell line (Rubinfeld et al., 1997) RRID: CVCL_4632 
Human: M990514 short-term cell culture URPP Live Tumor Cell Biobank, UZH N/A 
 Human: M010817 short-term cell culture URPP Live Tumor Cell Biobank, UZH N/A 
Human: M050829 short-term cell culture URPP Live Tumor Cell Biobank, UZH N/A 
Human: M070302 short-term cell culture URPP Live Tumor Cell Biobank, UZH N/A 
Human: M080423 short-term cell culture URPP Live Tumor Cell Biobank, UZH N/A 
Human: M130604 short-term cell culture URPP Live Tumor Cell Biobank, UZH N/A 
Human: M140130 short-term cell culture URPP Live Tumor Cell Biobank, UZH N/A 
Mouse: RIM-1 short-term cell culture (Zingg et al., 2015) N/A 
Mouse: RIM-3 short-term cell culture (Zingg et al., 2015) N/A 
Mouse: RIH-1 short-term cell culture This paper N/A 
Mouse: RIH-2 short-term cell culture This paper N/A 
Experimental Models: Organisms/Strains 
Mouse: Hsd:Athymic Nude-Foxn1nu/nu Envigo N/A 
Mouse: Tyr::CreERT2: B6.Cg-Tg(Tyr-
cre/ERT2)13Bos/J 
The Jackson Laboratory Cat# 012328; RRID: IMSR_JAX:012328 
Mouse: R26R-LSL-LacZ: B6;129S4-
Gt(ROSA)26Sortm1Sor/J 
The Jackson Laboratory Cat# 003309; RRID: IMSR_JAX:003309 
Mouse: R26R-LSL-tdTomato: B6.Cg-
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J 
The Jackson Laboratory Cat# 007914; RRID: IMSR_JAX:007914 
Mouse: Braf-LSL-BrafV600E: B6.129P2(Cg)-
Braftm1Mmcm/J 
The Jackson Laboratory Cat# 017837; RRID: IMSR_JAX:017837 
Mouse: Ptenlox: B6.129S4-Ptentm1Hwu/J The Jackson Laboratory Cat# 006440; RRID: IMSR_JAX:006440 
Mouse: Ezh2lox: B6;B6129-
Ezh2<tm1Yugo>/Hko 
(Hirabayashi et al., 2009) RIKEN_BRCM:RBRC05555 
Mouse: ColA1-LSL-Ezh2Y646N: Col1a1tm1(CAG-
Ezh2*)Meln 
(Béguelin et al., 2013) MGI: 5519911 
Mouse: Tyr::NrasQ61K: Tg(Tyr-
NRAS*Q61K)1Bee 
(Ackermann et al., 2005) MGI: 3768645 
Mouse: Cdkn2a–/–: Cdkn2atm1Rdp (Serrano et al., 1996) MGI: 1857942 
Oligonucleotides 
Mouse: Genotyping Primers, Braf-LSL-BrafV600E The Jackson Laboratory Cat# 017837 
Mouse: Genotyping Primers, Ptenlox The Jackson Laboratory Cat# 006440 
Mouse: Genotyping Primers, R26R-LSL-
tdTomato 
The Jackson Laboratory Cat# 007914 
Mouse: Genotyping Primers, See Table S2 Microsynth N/A  
Mouse: Genomic DNA Primers, Rpl30 Intron 2 Cell Signaling Technology Cat# 7015P 
Human: Genomic DNA Primers, RPL30 Exon 3 Cell Signaling Technology Cat# 7014P 
Custom Genomic DNA Primers, See Table S2 Microsynth N/A 
Human: Custom RT2 PCR Array, Spotted with 
Primary Cilium Gene and GAPDH primers 
Qiagen Cat# 330171 
Custom cDNA Primers, See Table S2 Microsynth N/A 
Recombinant DNA 
Stealth siRNA Negative Control Med GC Duplex 
#2 (siCo) 
Thermo Fisher Scientific Cat# 12935112 
Stealth siRNA targeting FUZ (siFUZ#1) Thermo Fisher Scientific Cat# HSS12946-0 
Stealth siRNA targeting FUZ (siFUZ#2) Thermo Fisher Scientific Cat# HSS12946-2 
Stealth siRNA targeting FUZ (siFUZ#3) Thermo Fisher Scientific Cat# HSS12946-1 
Stealth siRNA targeting IFT81 (siIFT81#1) Thermo Fisher Scientific Cat# HSS12077-6 
Stealth siRNA targeting IFT81 (siIFT81#2) Thermo Fisher Scientific Cat# HSS12077-7 
Stealth siRNA targeting IFT81 (siIFT81#3) Thermo Fisher Scientific Cat# HSS12077-5 
Stealth siRNA targeting WDR19 (siWDR19#1) Thermo Fisher Scientific Cat# HSS1-26738 
Stealth siRNA targeting WDR19 (siWDR19#2) Thermo Fisher Scientific Cat# HSS1-26737 
Stealth siRNA targeting WDR19 (siWDR19#3) Thermo Fisher Scientific Cat# HSS1-84043 
pGIPZ-non-silencing shRNA-TurboGFP (shCo) Dharmacon Cat# RHS4346 
pGIPZ-shKif3a-TurboGFP (shKif3a#1) Dharmacon Cat# RMM4431-20031-7419; Clone ID: 
V2LMM_122 
pGIPZ-shKif3a-TurboGFP (shKif3a#2) Dharmacon Cat# RMM4431-20031-8662; Clone ID: 
V2LMM_14535 
 pGIPZ-shWdr19-TurboGFP (shWdr19#1) Dharmacon Cat# VGM5520-20037-9129; Clone ID: 
V3LMM_457206 
pGIPZ-shWdr19-TurboGFP (shWdr19#2) Dharmacon Cat# VGM5520-20037-7417; Clone ID: 
V3LMM_457210 
pcDNA3.1-FLAG-CTNNB1S33Y (Valenta et al., 2011) N/A 
pMuLE-ENTR-CMV-L1-R5 (Albers et al., 2015), Addgene Cat# 62090 
pMuLE-ENTR-SV40-eGFP-L5-L2 (Albers et al., 2015), Addgene Cat# 62144 
pLenti-X1-Puro-DEST (Albers et al., 2015), Addgene Cat# 17297 
pMD2.G D. Trono Lab, Addgene Cat# 12259 
psPAX2 D. Trono Lab, Addgene Cat# 12260 
pRetroX-IRES-ZsGreen1 Clontech Cat# 632520 
pRetroX-EZH2WT-IRES-ZsGreen1 (Béguelin et al., 2013) N/A 
pRetroX-EZH2Y646N-IRES-ZsGreen1 (Béguelin et al., 2013) N/A 
pCL-Ampho Retrovirus Packaging Vector Novus Biologicals Cat# NBP2-29541 
Software and Algorithms 
Adobe Photoshop CS5 Adobe http://www.adobe.com/products/ 
photoshop.html 
Bioconductor 3.0 N/A https://www.bioconductor.org 
CellProfiler 2.1.1 (Carpenter et al., 2006) http://cellprofiler.org 
deepTools2 (Ramírez et al., 2016) https://deeptools.readthedocs.io/en/latest/ 
FastQC Babraham Bioinformatics http://www.bioinformatics.babraham.ac.uk/pro
jects/fastqc/ 
FlowJo 7.6 Tree Star https://www.flowjo.com 
GraphPad Prism 7 GraphPad Software https://www.graphpad.com 
ImageJ 1 (Schneider et al., 2012) http://imagej.net/ImageJ 
Integrative Genomic Viewer (Robinson et al., 2011) http://software.broadinstitute.org/software/igv/ 
MethPrimer 2.0 (Li and Dahiya, 2002) http://www.urogene.org/cgi-
bin/methprimer/methprimer.cgi 
PANTHER Classification System (Mi et al., 2013) http://www.pantherdb.org 
Primer-BLAST (Ye et al., 2012) https://www.ncbi.nlm.nih.gov/tools/primer-
blast/ 
R The R Foundation https://www.r-project.org 
R package edgeR (Robinson et al., 2010) https://bioconductor.org/packages/release/bioc/
html/edgeR.html 
R package GenomicRanges (Lawrence et al., 2013) https://bioconductor.org/packages/release/bioc/
html/GenomicRanges.html 
STAR 2.5.1b (Dobin et al., 2013) https://github.com/alexdobin/STAR/releases 
The UCSC Genome Browser (Kent et al., 2002) https://genome.ucsc.edu/index.html 
Trimmomatic (Bolger et al., 2014) http://www.usadellab.org/cms/index.php?page
=trimmomatic 
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Figure S1, related to Figure 1. EZH2 overexpression accelerates melanomagenesis. 
(A) Color-coded matrix of individual non-synonymous mutations and copy number changes arranged according to EZH2 mRNA 
expression, and frequency of EZH2 copy number changes (pie chart). Based on human skin cutaneous melanoma (SKCM) 
RSEM-normalized RNAseq, GISTIC2 copy number, and oncotated mutation datasets from The Cancer Genome Atlas (TCGA 
Network, 2015). Total specimen number, n = 278. (B) EZH2 mRNA expression in TCGA-SKCM dataset segregated according to 
genetic subtypes. BRAFV600*/K601*, n = 158; NRASG12*,G13*,Q61*, n = 83; NF1LoF, n = 35; Triple wild-type (WT), n = 43. NF1 loss-
of-function (LoF) defined by NF1 missense or nonsense mutation, frame shift insertion or deletion, and/or copy number loss, but 
BRAFWT and NRASWT. (C) EZH2 mRNA expression in A375 after transfection with empty vector, EZH2WT, or EZH2Y646N-
expression plasmids. (D) Western blots to quantify EZH2 protein and H3K27me3 intensities in A375 transfected with empty 
vector, EZH2WT, or EZH2Y646N-expression plasmids and treated with GSK503. (E) Fluorescence-activated cell sorting (FACS) to 
isolate tdTomato-traced RIH cells from homogenized dorsal skin (4 weeks post TM, 4-month-old mice). (F) FACS analyses to 
quantify retro-ZsGreen1-empty vector, EZH2WT, or EZH2Y646N infection efficiencies in tdTomato+ RIH cells. (G and H) Pictures 
(G) and Kaplan-Meier curves (H) comparing melanoma-specific survival of mice inoculated with RIH cells infected with retro-
empty vector, EZH2WT, or EZH2Y646N. Empty vector, EZH2WT, each n = 8; EZH2Y646N, each n = 7 mice. (I) FACS analyses to 
quantify ZsGreen1+ per tdTomato+ cells in tumors from mice in (H). (J) FACS analyses to quantify ZsGreen1+ td-tomato+ RIH 
cells in lungs from mice in (H). (K) FACS analyses to quantify retro-ZsGreen1-empty vector, EZH2WT, or EZH2Y646N infection 
efficiencies in RIM-1 cells. (L and M) Picture (L) and weight (M) of tumors derived from RIM-1 cells infected with retro-empty 
vector, EZH2WT, or EZH2Y646N, transplanted into Nude-Foxn1nu/nu mice, and treated with vehicle or tamoxifen (TM) to delete 
Ezh2. n = 5 mice per group. (N) Murine genomic Ezh2 deletion, murine Ezh2 mRNA expression, and human EZH2 mRNA 
expression in tumors from (M). cDNA primers are specific for mouse Ezh2 and human EZH2, respectively. Genomic primers 
amplify a fragment from murine Ezh2 Intron 18, which lies within the floxed segment of the Ezh2 locus (Hirabayashi et al., 
2009). (O) FACS analyses to quantify ZsGreen1+ cells in tumors from (M). Scale bars, 50 µm. Data are represented as median ± 
interquartile range (box) and ± 100% range (whiskers) (B) or as mean ± standard error of the mean (SEM) (C, D, F, I–K, and M–
O) of 3 (C) or 5 (D) independent experiments. p values calculated with analysis of variance (ANOVA) and Fisher’s least 
significant difference (LSD) test (B–D, J, and M–O), log-rank (Mantel-Cox) test (H), Kruskal-Wallis test with Dunn’s multiple 
comparisons test (J), or unpaired Student’s t-test (N). NS, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
  
  
 
Figure S2, related to Figure 2. Ezh2Y646N promotes murine melanoma formation. 
(A) Ezh2 mRNA expression in melanomas. BrafV600E;Pten–/–, n = 5 of 5; BrafV600E;Pten–/–;Ezh2Y646N, n = 6 of 6; 
NrasQ61K;Cdkn2a–/–, n = 20 of 14; NrasQ61K;Cdkn2a–/–;Ezh2Y646N, n = 15 of 10; and NrasQ61K;Cdkn2a–/–;Ezh2–/–, n = 20 of 13 
mice. (B) Western blots to quantify EZH2 protein, H3K27me3, and H3K27me2 intensities. n = 3 tumors of 3 mice per group. (C) 
Immunofluorescence staining for H3K27me3 and SOX10 or DCT to quantify H3K27me3 intensities. E, epidermis. Tumors, 
BrafV600E;Pten–/–, n = 5 of 5; BrafV600E;Pten–/–;Ezh2Y646N, n = 6 of 6; NrasQ61K;Cdkn2a–/–, n = 12 of 9; and NrasQ61K;Cdkn2a–/–
;Ezh2Y646N, n = 12 of 10 mice. (D) Immunofluorescence staining for KI67 and SOX10 or PAX3. Quantifications are in Figures 
2C and 2D. Arrowhead, KI67+ and SOX10+ or PAX3+ cell.  (E) BrafV600E;Pten–/– and BrafV600E;Pten–/–;Ezh2Y646N animal during 
melanoma development post topical 4 hydroxytamoxifen (4-OHT) application. Scale bars, 50 µm. Data are represented as mean ± 
SEM. p values calculated with unpaired Student’s t-test (A–C) or ANOVA and Fisher’s LSD test (A).  
  
 
Figure S3, related to Figure 3. Ezh2Y646N is a driver of murine metastatic melanoma. 
(A) Mouse genotype and strategy used to analyze the effect of conditional Ezh2Y646N activation in the melanocytic lineage of 
adult WT mice. (B) WT and Ezh2Y646N animal post TM administration and 4 cycles of hair depilation in labeled area on back 
skin. (C and D) Endogenous tdTomato fluorescence and immunofluorescence staining for DCT or bright field (BF) to quantify 
recombined hair follicles (HF) (C) and pigmented HFs (D) in dorsal skin. Scale bars, 100 µm. WT, n = 8; Ezh2Y646N, n = 6 mice. 
(E and F) Immunofluorescence staining for PAX3, DCT, KI67, and tdTomato on dermal hyperplasia to quantify proliferative (E) 
and recombined (F) cells 5 months post TM administration. D, dermis. Arrowhead, PAX3+ KI67+ or DCT+ tdTomato+ cell; empty 
arrowhead, DCT+ tdTomato– cell. Scale bars, 50 µm. n = 6 mice per group. (G) NrasQ61K and NrasQ61K;Ezh2Y646N animal 12 
months post TM administration. (H) Immunofluorescence staining for tdTomato on dorsal skin. Quantifications are in Figure 3G. 
Scale bars, 1 mm. (I) Immunofluorescence staining for PAX3 and tdTomato on skin melanomas and lymph node metastases. 
Quantifications are in Figure 3J. Scale bars, 50 µm. Data are represented as mean ± SEM. p values calculated with unpaired 
Student’s t-test.  
 
 
  
 
 Figure S4, related to Figure 4. EZH2 suppresses transcription of primary cilium genes. 
(A) FACS to isolate tdTomato-traced NrasQ61K, NrasQ61K;Ezh2Y646N, BrafV600E, and BrafV600E;Ezh2Y646N hyperplasia cells from 
homogenized dorsal skin (4 weeks post TM, 10-week-old mice). (B) RNA-sequencing on murine FACS-isolated 
NrasQ61K;Ezh2Y646N versus (vs.) NrasQ61K hyperplasia cells. n = 2 per group. FDR < 0.005, p < 0.01, Log2 fold change (FC) > +0.7 
/ < –0.7 was considered significant. (C) PANTHER GO-slim biological processes analysis using Overrepresentation Test and 
Fisher’s Exact test with FDR multiple test correction (Mi et al., 2013) on RNA-sequencing data from murine FACS-isolated 
NrasQ61K;Ezh2Y646N vs. NrasQ61K hyperplasia cells. (D) PANTHER GO cellular component complete analysis using 
Overrepresentation Test and Bonferroni correction (Mi et al., 2013) on transcriptome data from M010817 and M050829 
melanoma cell cultures after EZH2 RNAi (GSE63165). (E) Enrichment plots showing normalized read densities of H3K27me3 at 
the transcription start site (TSS) of SYSCILA (van Dam et al., 2013) and random genes (each n = 760) in human melanoma cell 
cultures (GSE60666). Tracks are centered to the TSS and extend ± 5 Kb. (F) Genome browser tracks showing H3K27me3 at 
CCDC113 and CELSR2 loci in human melanoma cell cultures (GSE60666). (G–I) Western blots for EZH2 and H3K27me3 (G) 
to quantify global H3K27me3 levels (H) and efficacy of GSK503 (I) in melanoma cell lines. N/A, not available. (J) Heatmap 
showing ciliary gene mRNA FCs in melanoma cell lines treated with GSK503 vs. vehicle and analyzed with Custom RT2 PCR 
Array spotted with primers for human primary cilium genes. Log10 gains in cilia values are based on Figure 4C. Correlations are 
calculated across cell lines comparing FCs of individual genes versus Log10 gain in cilia. Colored squares indicate significant FC 
or Spearman’s rank correlation coefficient (rS) (p < 0.05). (K) ChIP-qPCR on chromatin from M050829 cells treated with 
GSK503 vs. vehicle. A control IgG antibody (IgG-Co) or an antibody against H3K27me3, primers amplifying the negative 
control genomic sequence of RPL30 Exon 3 (E3), and primers flanking the transcriptional start sites (TSS) of key ciliary genes 
were used. Data was normalized to input and IgG-Co sample of cells treated with vehicle. (L) Heatmap showing H3K27me3 
enrichments in TSS of ciliary genes. ChIP-qPCR normalized to input and H3K27me3 enrichments in vehicle-treated samples. 
Colored squares indicate significant fold enrichment (p < 0.05). Conditions as in (J). (M) Heatmap showing relative ciliary gene 
expression in melanoma cell lines. Log10 percentages of ciliated cells are based on Figure 4C. Correlations are calculated across 
cell lines comparing relative gene expression versus Log10 ciliated cells. Colored squares indicate significant relative increase in 
gene expression compared to the lowest value (normalized per gene) or significant Spearman’s rS (p < 0.05). (N) Heatmaps 
showing ciliary gene mRNA FCs and H3K27me3 enrichments in TSS of ciliary genes. Material from A375 transfected with 
empty vector, EZH2WT, or EZH2Y646N-expression plasmids and treated with GSK503 vs. vehicle. mRNA expressions analyzed 
with Custom RT2 PCR Array spotted with primers for human primary cilium genes. ChIP-qPCR normalized to input and 
H3K27me3 enrichment in RPL30 E3 of empty vector-transfected and vehicle-treated samples. Colored squares, significant FCs 
over this enrichment or individual gene expressions of empty vector-transfected and vehicle-treated samples (p < 0.05). (O) 
Heatmap showing H3K27me3 enrichments in TSS of ciliary genes. ChIP-qPCR normalized to input and H3K27me3 enrichment 
in Rpl30 Intron 2 (I2) and intergenic region 1 (Interg1) of all RIH tumors. Tumors, RIH-2–EZH2WT, n = 2 of 2; other groups, n = 
3 of 3 mice. (P) Mouse genotypes and strategy used to analyze the effect of conditional Ezh2 deletion in established melanoma of 
adult NrasQ61K;Cdkn2a–/– mice. (Q) Heatmaps showing ciliary gene FCs in murine samples and p values from comparisons of 
individual groups. Tumors, NrasQ61K;Cdkn2a–/–, n = 20 of 14; NrasQ61K;Cdkn2a–/–;Ezh2Y646N, n = 15 of 10; NrasQ61K;Cdkn2a–/–
;Ezh2–/–, n = 20 of 13; BrafV600E;Pten–/–, n = 5 of 5; and BrafV600E;Pten–/–;Ezh2Y646N, n = 6 of 6 mice. Data are represented as mean 
± SEM (H, I, and K) or as mean (J and L–N) of 3 independent experiments. p values calculated with unpaired Student’s t-test (I, 
J, and L), Spearman’s rS (J and M), or ANOVA and Fisher’s LSD test (K, M–O, and Q).  
 Table S1, related to Figure 4. Tumor suppressor genes. 
Gene FDR Log2 FC p value 
Apc 0.9658 -0.05719 0.8367 
Cdkn1a 0.1426 0.6449 0.01819 
Cdkn1b 0.6288 -0.3408 0.2096 
Coro1a 0.8688 -0.2961 0.5146 
Cdkn2a 0.905 0.2504 0.6022 
Cdkn2b 0.7617 0.2809 0.3303 
Cdkn2c 0.9398 -0.109 0.7207 
Nf1 0.7261 -0.2861 0.2923 
Nf2 0.899 -0.148 0.5869 
Pten 0.6614 -0.3319 0.2347 
Rb1 0.9598 0.06783 0.8032 
Trp53 0.7921 -0.2464 0.3684 
 
 
  
  
 
Figure S5, related to Figure 5. EZH2 expression leads to deconstruction of the primary cilium organelle. 
(A and B). Quantifications of ciliation (A) and nuclear EZH2 intensity (B) of MART1+ melanocytic lesions. Based on immuno-
fluorescence stainings in Figure 5A and sample numbers as in Figure 5B. (C) Immunofluorescence staining for ARL13B and 
PCNT to label ciliated melanoma cells during GSK503 treatment. Quantifications are in Figure 5C. (D) Correlation of relative 
H3K27me3 and percentages of ciliated melanoma cells. Based on data from Figures 5C and S4H. (E) Immunofluorescence 
stainings for ARL13B and DCT or tdTomato on melanomas and adjacent hyperplasia. Arrowhead, ARL13B (cilia)+ DCT+ cell; 
empty arrowhead, ARL13B (cilia)– tdTomato+ cell. Quantifications are in Figures 5F and 5G. Scale bars, 25 µm. Data are 
represented as mean ± SEM (A), as median ± interquartile range (box) and ± 100% range (whiskers) (B), or as mean ± 100% 
range (D). p values calculated with ANOVA and Fisher’s LSD test (A and B) or Spearman’s rS (D).  
  
 
 
  
 
 
 
 
  
 
Figure S6, related to Figure 6. Loss of primary cilia induces WNT/β-catenin signaling. 
(A) WDR19, FUZ, and IFT81 mRNA expression in A375 cells after transfection with siRNAs targeting these genes (top panel), 
and Wdr19 and Kif3a mRNA expression in RIH cells after infection with lenti-viruses targeting these genes (bottom panel). 
Black arrows, siRNAs chosen for further experiments. (B) Immunofluorescence staining for acetylated tubulin (AcTub) and 
PCNT to quantify ciliated A375 cells transfected with siCo, siWDR19, siFUZ, or siIFT81. Scale bars, 25 µm. (C) 
Immunofluorescence staining for GFP and ARL13B to quantify ciliated GFP+ RIH cells infected with lenti-GFP-shCo, shWdr19, 
or shKif3a. Scale bars, 50 µm. (D) Luciferase reporter assays on RIH cells infected with lenti-shCo, shWdr19, or shKif3a and 
transfected with empty vector or TCF/LEF reporter plasmid after 3 hr stimulation with vehicle or WNT3A. Relative luciferase 
units (RLU) calculated by normalizing firefly luciferase to Renilla luciferase luminescence. (E) Immunofluorescence staining for 
AcTub, PCNT, and non-phosphorylated (nonP) β-catenin on A375 transfected with siCo, siWDR19, or siFUZ and stimulated 
with WNT3A. Scale bars, 25 µm. (F) Western blots for total and nonP-β-catenin on cytoplasmic and nuclear fractions of RIH-1 
infected with lenti-shCo, shWdr19, or shKif3a, treated with JW55, and stimulated with WNT3A. (G) Luciferase reporter assays 
on A375 co-transfected with siCo, siWDR19, or siFUZ and TCF/LEF reporter plasmid and treated with JW55 or PRI-724. All 
samples stimulated with WNT3A. (H) Luciferase reporter assays on RIH cells infected with lenti-shCo, shWdr19, or shKif3a, 
transfected with TCF/LEF reporter plasmid, and treated as in (G). (I) Quantification of nuclear β-catenin intensity of MART1+ 
melanocytic lesions. Based on immunofluorescence stainings in Figure 6C and sample numbers as in Figure 5B. (J) Nuclear 
EZH2 and β-catenin intensities correlation across melanocytic lesions. Based on data from (I) and Figure S5B. (K) Luciferase 
reporter assays on A375 co-transfected with empty vector, EZH2WT, or EZH2Y646N-expression and TCF/LEF reporter plasmids, 
treated with GSK503, and stimulated with WNT3A. (L) AXIN2 mRNA expression in A375. Conditions as in (K), except without 
TCF/LEF reporter plasmid. (M) Luciferase reporter assays on A375 transfected as in (K) and treated with GSK503, JW55, or 
PRI-724. All samples stimulated with WNT3A. (N) Axin2 mRNA expression. Mouse tumor numbers as in Figure S4Q. (O) 
 WDR19, FUZ, and IFT81 mRNA expression in M130604 after transfection with siRNAs targeting these genes and treatment with 
GSK503. (P and Q) Immunofluorescence staining for ARL13B and PCNT (P) to quantify ciliated M130604, WM983B, and 
M050829 melanoma cells transfected with siCo, siWDR19, siFUZ, or siIFT81 and treated with GSK503 (Q). Scale bars, 25 µm. 
(R) Luciferase reporter assays on M130604 transfected with siCo, siWDR19, or siFUZ and TCF/LEF reporter plasmid, treated 
with GSK503, and stimulated with WNT3A. (S) AXIN2 mRNA expression in M130604. Conditions as in (R), except without 
TCF/LEF reporter plasmid. (T) Luciferase reporter assays on M130604 transfected as in (R) and treated with GSK503, JW55, or 
PRI-724. All samples stimulated with WNT3A. Data are represented as mean ± SEM (A–H and K–T) of 3 independent 
experiments (A–H, K–M, and O–T) or as median ± interquartile range (box) and ± 100% range (whiskers) (I). p values calculated 
with ANOVA and Fisher’s LSD test (B–I, K–M, and O–T), Spearman’s rS (J), or unpaired Student’s t-test (N).  
  
 
Figure S7, related to Figure 7. Primary cilium disassembly and WNT/β-catenin signaling promote melanoma growth. 
(A) Colony formation assay of RIH-1 infected with lenti-shCo, shWdr19, or shKif3a and treated with JW55 or PRI-724. 
Quantifications are in Figure 7C. (B) Growth curves of M130604 and density after 7 days of M130604, WM983B, and M050829 
 transfected with siCo, siWDR19, siFUZ, or siIFT81 and treated with GSK503. (C and D) Clonogenicity of A375 (C) and RIH-1 
(D) transfected with empty vector, EZH2WT, or EZH2Y646N-expression plasmids and treated with JW55 or PRI-724. (E) 
Luciferase reporter assays on 501Mel (endogenous CTNNB1S37F) cells transfected with TCF/LEF reporter plasmid, treated with 
GSK503, and stimulated with WNT3A. (F) Immunofluorescence staining for nonP-β-catenin on 501Mel treated with GSK503 or 
stimulated with WNT3A. Scale bars, 25 µm. (G) Clonogenicity of 501Mel treated with GSK503. (H) Luciferase reporter assays 
on M130604 co-transfected with empty vector or CTNNB1S33Y-expression and TCF/LEF reporter plasmids and treated with 
Chiron or GSK503. (I) Western blots for total and nonP-β-catenin on cytoplasmic and nuclear fractions of M130604 transfected 
with empty vector or CTNNB1S33Y-expression plasmid and treated with Chiron or GSK503. Data are represented as mean ± SEM 
of 3 (B, E, and H) or 4 (C, D, and G) independent experiments. p values calculated with ANOVA and Fisher’s LSD test (B–D, E, 
and H) or unpaired Student’s t-test (G).  
  
 
 
 
 
  
 
Figure S8, related to Figure 8. Primary cilium deconstruction is sufficient to initiate metastatic melanoma. 
(A) Wdr19 mRNA expression in RIM-3 cells infected with lenti-GFP-shCo or shWdr19. (B) Immunofluorescence staining for 
GFP and ARL13B to quantify ciliated GFP+ RIM-3 infected with lenti-shCo or shWdr19. Scale bars, 50 µm. (C) Wdr19 mRNA 
expression in tumors derived from RIM-3 infected with lenti-shCo or shWdr19, transplanted into Nude mice, and treated with 
vehicle or GSK503. Mouse numbers as in Figure 8B. (D) Picture of tumors from mouse cohorts in Figure 8B. (E and F) Picture 
(E) and Kaplan-Meier curves (F) comparing melanoma-specific survival of mouse cohorts in Figures 8G and 8H. (G and H) 
FACS analyses to quantify GFP+ td-tomato+ cells in tumors (G) and lungs (H) from mice in Figures 8G and 8H. Quantifications 
are in Figure 8I. (I) Luciferase reporter assays on RIH cells infected with lenti-empty vector or CTNNB1S33Y and transfected with 
TCF/LEF reporter plasmid. (J and K) Picture (J) and Kaplan-Meier curves (K) comparing melanoma-specific survival of mouse 
cohorts in Figure 8J. (L and M) FACS analyses to quantify GFP+ td-tomato+ cells in CTNNB1S33Y tumors (L) and lungs (M) from 
mice in Figure 8J. Quantifications are in Figure 8K. (N) Western blot to quantify β-catenin intensities of second-generation 
tumors derived from a RIH-1–EZH2Y646N tumor (Figure 1E) and treated with vehicle or JW55. Quantification is in Figure 8L. (O) 
Pictures of mice in Figures 8N and 8O. Data are represented as mean ± SEM (A–C and I) of 3 independent experiments (A, B, 
and I). p values calculated with ANOVA and Fisher’s LSD test (B and C), log-rank (Mantel-Cox) test (F and K), or unpaired 
Student’s t-test (I).  
 Table S2, related to STAR★METHODS. Primers. 
GENE FORWARD SEQUENCE REVERSE SEQUENCE 
Cloning primers 
BamHI-CTNNB1 ATATGGATCCATGGCTACTCAAGCTGAC  
CTNNB1-EcoRI  GCCGTCTAGATTACAGGTCAGTATCAAACCA 
Mouse genotyping primers 
Cre CTATCCAGCAACATTTGGGCCAGC CCAGGTTACGGATATAGTTCATGAC 
Ezh2WT AAGGCTGTGTACAGGAAACAATC AGTACTCCAGAGGTACTGAAGTTTG 
Ezh2lox AAGGCTGTGTACAGGAAACAATC TCACCTTAATATGCGAAGTGGAC 
Ezh2Y646N TTTCTGTGCCATTGCTAGGT ACTTTCCCTCTTCTGTCAGC 
Cdkn2aWT ATGATGATGGGCAACGTTC CAAATATCGCACGATGTC 
Cdkn2aKO CTATCAGGACATAGCGTTGG AGTGAGAGTTTGGGGACAGAG 
LacZ GGTCGGCTTACGGCGGTGATTT AGCGGCGTCAGCAGTTGTTTTT 
NrasQ61K GATCCCACCATAGAGGATT CTGGCGTATTTCTCTTACC 
Mouse qPCR primers for cDNA 
Axin2 AGAGGGACAGGAACCACTCG GGACACTTGCCAGTTTCTTTGG 
Ccdc113 GCTGAGAAACGAGCTACTTGG AGATATGGGCTTTGGCCCTG 
Celsr2 CCCTGCCTTGACCACTAAGTC GCCGAATCTCCGTAAGGCTG 
Ezh2 GTGACCACAGGATAGGCATCT CAAGGGATTTCCATTTCTCG 
Fuz GAAACTTCTACACGCTGGTGG TGGCCCTAGCACGAGATAAC 
Ift81 GTTGACGAGATGAAAGGCCG TTTCTGACGCAACTGCCGTA 
Kif3a AGCTCCGTCTTCAGATGCTC GCCACACATTTTAGCTGCCA 
Lztfl1 ACAGCTCGATCAAGAAAACCAAC TGCAACTGTATTTTCCAAGTCATCC 
Tulp3 ACCATGGTGTCAACCCAGTC TCCTGGGACCTTTGAAACCG 
Usf1 CAGGGCTCAGAGGCACTACT GCTCCCTCCCTGCAATACTT 
Wdr19 ACCACCCCATGTCCATTCTG CGTCTTTCAACATGTGTCGGC 
Wdr63 TGGACCTTAAGTCACCCTTCC TGCTGGACGTATTCCAGGTG 
Human qPCR primers for cDNA 
AXIN2 CAGGTCGCAGGATGTCTGG GGGCAGACTCCAAGGGGTA 
CCDC113 TGGACAAGGAGATCTTGCTGAG CTCTTATTCACTGCCTCGGCT 
EZH2 GCTTCCTACATCGTAAGTGCAA AGCAAACTCCTTTGCTCCCT 
FUZ GTGGAGCCCTTGGGGGATA CTCATCTTCTGTCTTCTCTGGTGG 
IFT81 ATCTTGCACAACAGAAACAGGAAC TGCTTTTCAGCTGGTTTTGTACTC 
LZTFL1 AGCCAAGCACGATCTACTCAG TTCGATAAGCTGCTGTTTGCTG 
NDEL1 TGGCAATGGCACAAAGTTCTC CCGTTTACTGCCCCATGAAC 
USF1 TACTACCCAGGGCTCAGAGG TCCCTGCAGTACTTCTTGTGG 
WDR19 TGATGAGGCCTGAATACCGC AATGGACATGGAGTCGTGGC 
WDR63 TTAAGTCGCCCTTCCACCAA CGCTGTTCTACGTATTCCAGATG 
Mouse qPCR primers for genomic DNA 
Ccdc113 GGGGCAGAGACTTATGCGAG CAAATCTTTGCATGGACCCTGTT 
Celsr2 CGCAGGTAGAGAACGCTCAG CTCCCACCACTCTCGAAGC 
Ezh2 Intron 18 CAAGTGACAGCAAACTTCAGTACC ACTGCAAAGAGAAACATTGGCAG 
Fuz GCAACACCTTAGCACCATCAC TGCCAAGCGTTCAAGTTGTTC 
Ift81 GTCGCCCCAAGTTTGGTAAATAA CCGTCTACCGTTCTCACCTTG 
Interg1 GCTCCGGGTCCTATTCTTGT TCTTGGTTTCCAGGAGATGC 
Lztfl1 AAGTTATTCTCTTCTGCCAGCGT TCCGGCTATCAAGCTCATGC 
Tulp3 ATTTGCTGAAGGTCCCCAGG CATCTGACCACCGACTCTGG 
Wdr19 GCTCACATAGCTCAAGACCCTT AGTTGAATGCTACGAGGGCT 
Wdr63 CTGGGCTTCTCTGGGATTACG TATCCGCTCCCCAACATTGTC 
Human qPCR primers for genomic DNA 
ARL13B ACCGTGGATTGGCAACACAT GTAACTAGGCAACCGGAGCG 
BBS2 CTAGACCGAACGTGAGTCTAAGG TATTCCTTGAGTGTCGGCTCTG 
BBS4 TGTTAGGGGCTTCTCGGGAT TCTGCTCCACAGAAGGCTTAC 
CCDC113 GGTTGTGGCGAAGGTTTTCA GCAGCTGCTGTTTCTCAGC 
CELSR2 TCAGGGGGCAGTGGGAG CTGCGTCTGGATGGCTCG 
DYNC2H1 CGACGCCGCCGTAGTG ACCCGTAGCCCGACCG 
DYNC2LI1 CTTGGCATATAGTTGACACCCAG CTCCTAGAACGAGATGATAAGGGG 
FUZ ACCTACAGGGAATGTGGTTGC AAAACAGCTGTGCCCGGAT 
IFT81 TTTTGTAAACTGCGAAGTGCAGG TTTGGGACTGTTACTCCGACC 
IFT88 CATCCTTTGGGCATCTGCTTTAC AGGGGAAGGATATGGAACCAAG 
IFT140 AAAACGGCGCTCCCATTG GCGTCACAACACTACTGGC 
INTU GCTGCTCTAAGGAATTGCGTTC AGGAGGGCTTCTCAGTTGGA 
INVS AAATGTAGTCCTGCACTAGCCTC GAGCCCAATGGGAAAGGAAGTT 
 LZTFL1 GCGCCCTATGAGACCATTGA GTCCAGAACTTCCTGTGGCA 
STIL CACCAATACGTAACGGCGAC TGACTGGTCAGAAACCTCGC 
TULP3 GAGGACCAAGCCTTAGCTCG GATGCGGGAGGGTTGCTAAG 
VANGL2 TTCTCCGACAGGAGGGGTC GGAATGCCTCGATTCTTGGACT 
WDR19 TCTTATGCCTCCTCCCTTCTACC TCCTATACAGTCCACGCAAAGAG 
WDR63 TTCCTAGGGTCCACACCCC AGGTCTAACAGGCTCGGTCC 
 
 
